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ABSTRACT
Metabolic syndrome (MetS) encompasses metabolic abnormalities that substantially
increase risk for chronic illnesses. MetS and stress are closely related; the pathophysiology of
MetS involves dysregulated stress response in both the physiological and psychological domains.
In an effort to further clarify the relationship between metabolic abnormalities and autonomic
dysregulation, we used ambulatory impedance cardiography (ICG) to examine indicators of
cardiac autonomic control (CAC) in a sample of 50 adult primary care patients with and without
MetS. Indices of sympathetic and parasympathetic influences on cardiovascular functioning were
assessed in the context of psychological stressors and compared across experimental groups and
examined in relation to self-reported health measures. Primary results suggest that while our
experimental groups did not differ significantly on baseline measures, patterns of responses to
experimentally induced stressors were largely consistent with our predictions, and demonstrate
that individuals with MetS responded to stress cues with more maladaptive CAC scores.
Moreover, in line with previous work, we found that elements of CAC in our sample were
predictive of both cardiovascular disease and self-reported environmental quality of life. Overall,
our results suggest that maladaptive physiological manifestations of the stress response are
evident among individuals with MetS and may also be related to long-term health outcomes. The
present study carries implications for both evaluation and assessment as well as treatment
delivery and monitoring. In addition, the ambulatory nature of data collection demonstrated here
supports trends toward mHealth and related initiatives in emerging modes of healthcare
delivery.
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW
Metabolic syndrome (MetS; also labeled “insulin resistance syndrome,” DeFronzo, &
Ferrannini, 1991) represents a constellation of metabolic abnormalities that substantially increase
risk for cardiovascular disease (CVD) and diabetes mellitus, type 2 (DM2). MetS is related
closely to lifestyle factors (Grundy et al., 2006; Tentolouris, Argyrakopoulou, & Katsilambros,
2008), but stress also contributes to the development and maintenance of MetS (Blumenthal et
al., 2012; Hjemdahl, 2002; Rosmond, 2005; Schwartz et al., 2003; Vitaliano et al., 2002).
Moreover, embodied psychological phenomena during periods of stress are important
determinants of illness (Adler, 2002; Blascovich & Mendez, 2000; Burke, Davis, Otte, & Mohr,
2005; Cacioppo & Tassinary, 1990; Carroll et al., 2012; Celano et al., 2013; Lambert,
Straznicky, Lambert, Dixon, & Schlaich, 2010; Prkachin, Williams-Avery, Zwaal, & Mills,
1999). In MetS, one unresolved issue involves the extent to which these determinants are
pathophysiological, and how these determinants relate to disease progression. The purpose of
this investigation is to examine cardiovascular responses to stress among individuals with MetS
and to explore the impact of these responses on health behavior and treatment adherence.
Metabolic Syndrome
Clinical Features
MetS is not a new condition (Kylin, 1923), and a growing body of research has
dramatically improved our understanding of its role in chronic illness. In an effort to reconcile
discrepant diagnostic criteria, The American Heart Association and the National Heart, Lung,
and Blood Institute (NHLBI; Grundy et al., 2006), issued a joint report clarifying the five clinical
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features of MetS. They include (1) elevated waist circumference, (2) elevated triglycerides (3)
reduced high-density lipoprotein (HDL) cholesterol, (4) elevated blood pressure (BP) and (5)
elevated fasting blood glucose (fBG). Table 1 outlines MetS criteria as defined by the NHLBI.
Table 1. Metabolic Risk Measurement and Diagnostic Criteria for Metabolic Syndrome
Measure

Clinical Threshold/Cutoff

Normal Range

1. Waist circumference

≥ 102 cm in men
≥ 88 cm in women
≥ 150 mg/dL
– or –
On drug treatment for elevated
triglycerides
< 40 mg/dL in men
< 50 mg/dL in women
– or –
On drug treatment for reduced HDL
≥ 130 mm Hg systolic
– or –
≥ 85 mm Hg diastolic
– or –
On antihypertensive drug treatment in
a patient with a history of
hypertension

< 102 cm in men
< 88 cm in women
< 150 mg/dL

2. Triglycerides

3. High-density lipoprotein

4. Blood pressure

5. Fasting glucose

40-49 mg/dL in men
50-59 mg/dL in women
– or –
60 mg/dL and above
≤ 120 mm Hg systolic
≤ 80 mm Hg diastolic

≥ 100 mg/dL

70-99 mg/dL
– or –
On drug treatment for elevated
glucose
Note: Adapted from Grundy et al. (2006) Reprinted with permission, Circulation.2005;112:27352752, ©2005, American Heart Association, Inc.; Additional sources: The Mayo Clinic,
These risk factors are all interrelated, and while visceral adiposity (Carr et al., 1994) and
insulin resistance (Ferrannini, Haffner & Mitchell, 1991) are thought to underlie metabolic
abnormalities, there is most likely not a single cause for the syndrome (Grundy et al., 2006;
Canale et al., 2013).
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Developmental Features
Onset of MetS is difficult to determine because the component features develop
gradually, and can wax and wane in the early stages of the syndrome. Genetic factors predispose
individuals to some degree of metabolic dysregulation. There is evidence that genetically
moderated hormonal hypersensitivity along the hypothalamic-pituitary-adrenal (HPA) axis is
important in the maintenance of MetS (Rosmond, 2005). It appears also that metabolic and
biochemical processes differ as a function of race (Anderson, McNeilly, & Myers 1993; Haffner
et al., 1996), corroborating genetic contributions. Such biological and genetic influences become
amplified by lifestyle factors including physical inactivity and poor diet.
Lifestyle factors increase the propensity for obesity and insulin resistance, the two
underlying risk factors for MetS. Park et al. (2003) studied lifestyle and physiological variables
that contribute to MetS in a sample of 12,363 individuals drawn from the Third National Health
And Nutrition Examination Survey (NHANES III). Findings indicate that men (who are at an
increased risk for metabolic syndrome, Katano et al., 2010), were significantly more likely to
develop MetS if they were inactive and consumed high quantities of carbohydrates. Other
lifestyle variables (e.g., smoking, alcohol use) are linked to increased odds of developing MetS
(Katano et al., 2010; Park et al., 2003; Zhu, St. Onge, Heshka, & Heymsfield, 2004). Therefore,
treatment for MetS first and foremost incorporates behavior change and lifestyle modification.
Stress and Metabolic Risk
Stress increases metabolic risk, and has been associated with MetS and other chronic
conditions on theoretical and empirical grounds (Blumenthal et al., 1995; Brunner et al., 2002;
Canale et al., 2013; Koivistoinen et al., 2010; Novak et al., 2013; Rosmond, 2005; Tentolouris et
3

al., 2008; Thayer, Yamamoto, & Brosschot, 2010). Several trends in the literature support this
conclusion.
First, prevalence rates of MetS are higher among individuals facing chronic psychosocial
stressors compared to those who are not. It has been estimated that between 6% and 23% of the
variance in MetS can be attributable to chronic stress (Vitaliano et al. 2002). Chandola, Brunner,
and Marmot (2006) analyzed data from over ten thousand individuals in the Whitehall II study
and found that the accumulation of chronic work stress over a 14-year period increased odds for
MetS development by 125 percent.
Second, physiological mechanisms underlying insulin resistance and obesity have been
linked to autonomic activation (Canale et al., 2013; Flaa et al., 2008; Hjemdahl, 2002; Lambert
et al., 2010). Masuo, Mikami, Ogihara, and Tuck (1997) concluded that heightened physiological
activation was predictive of obesity and hypertension over a 10-year period among both
hypertensive and normotensive adults. This association has been argued on conceptual grounds
as well. Julius, Valentini, and Palatini (2000) proposed that physiological activation in response
to stress impacts obesity directly through altering beta-adrenergic sensitivity, and indirectly
through increasing insulin resistance.
Finally, several studies have concluded that autonomic dysregulation precedes
development of MetS (DeCouck, Mravec, & Gidrron, 2012; Koivistoinen et al., 2010; Masi,
Hawkley, Rickett, & Cacioppo, 2007; Tentolouris et al., 2008, Thayer et al., 2010). Notably,
Chang et al. (2010) examined a sample of pre-disease participants at risk for MetS and found that
those with more risk factors evidenced maladaptive physiological stress patterns in response to
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standardized stressors. In addition, Licht and colleagues (2013) found that in a sample of 1933
adults, measures of autonomic dysregulation were predictive of MetS risk factors two years later.
A core theme in the investigations described above is cardiovascular reactivity (CVR).
The physiology of CVR and the anatomy of the cardiovascular system (CVS) are central
indicators of the body’s typical stress response and can help clarify why stress becomes
pathogenic for these patients (Curtis & O’Keefe, 2002; Lambert et al., 2010; Soares-Miranda et
al., 2012; Tentolouris et al., 2008).
The Cardiovascular System
The heart, arteries, veins, and capillaries constitute the CVS – a system highly responsive
to biological and environmental changes. The CVS is under the control of both intrinsic and
extrinsic mechanisms (Berntson, Quigley, & Lozano, 2007; Andreassi, 2007).

Figure 1. Anatomy and Physiology of Electrical Elements Controlling the Cardiac Cycle.
Adapted from Berntson et al. (2007). Note: Dotted lines denote direction of depolarization; RA =
Right Atrium; LA = Left Atrium; RV = Right Ventricle; LV = Left Ventricle.
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Intrinsic Control
Electrochemical activity within the myocardium controls the cardiac cycle. The cardiac
cycle refers to the sequence of events in the heart that occur from one beat to another. The cycle
consists of two epochs: systole, during which myocardium contracts and pumps blood, and
diastole, during which the myocardium relaxes and the chambers fill with blood (Berntson et al.,
2007; Andreassi, 2007).
Systole and diastole occur through depolarization of electrically active muscle fibers
within the heart beginning in the sinoatrial (SA) node located in the right atrium (see Figure 1).
Depolarization travels downward to the atrioventricular (AV) node, initiating contraction of the
atria, and completely filling the ventricles. The electrical impulse propagates down the right and
left bundle branches terminating in the Purkinje network. This final sequence of depolarization
causes ventricular contraction, which ejects blood toward the periphery and lungs. Polarization
occurs during the diastolic epoch as negative pressure builds in the ventricles, causing an inflow
of blood to the atria (Andreassi, 2007).
Electrocardiogram (ECG) is a common method used to assess cardiac function
(Andreassi, 2007; Berntson et al., 2007). ECG records electrical fluctuations on the surface of the
skin caused by myocardial depolarization. This electrical fluctuation translates to a specific
waveform, characterized by upward and downward deflections over time. In the ECG signal, the
QRS complex denotes depolarization down the AV bundle and corresponds to ventricular
contraction. This signal is used to derive measures of cardiac activity including heart rate (HR)
and heart rate variability (HRV). Figure 2 depicts the standard ECG waveform (including the
QRS complex) and identifies corresponding physiological features of the cardiac cycle.
6
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Figure 2. Comparison of Physiological, Electrical, and Phonographic Features of the Cardiac
Cycle Over Time. (Adapted from Berntson et al., 2007).
Impedance cardiography (ICG) is a non-invasive procedure that permits measurement of
physiological features in the heart. ICG records the voltage differential between opposing pairs
of dorsal and ventral sensors by applying a high-frequency, constant-current electrical flow to the
torso. Contrary to ECG’s measurement of electrical activity, ICG facilitates computation of
systolic (pre-ejection period) and volumetric indices (e.g., stroke volume) of cardiac functioning.
There is some evidence that hemodynamics in individuals with MetS may be compromised (i.e.,
irregular; Wahba & Mak, 2007) due to the significant impact of metabolic dysregulation on the
cardiovascular system. However, in a thorough investigation involving approximate entropy
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(ApEn) analysis, Guerra et al. (2011) did not detect differences in systolic or volumetric ICG
indices between MetS patients and healthy controls.
The vasculature is also under control of intrinsic mechanisms that regulate blood flow
and pressure. Blood flow (F) within a vessel is a function of the pressure differential along a
gradient (i.e., between point 1 and point 2; P1-P2) and the inverse of the resistance (R) to that
flow, such that F = (P1-P2)/R. That is, along a constant pressure gradient, flow decreases as
resistance increases. Whereas resistance depends on persistent factors such as blood viscosity
and local intravascular conditions (e.g., atherosclerosis), blood pressure (BP) depends on
transient factors such as cardiac output (CO) and vasoconstriction/dilation (Andreassi, 2007).
Therefore, regulation of BP is the most efficient means of manipulating momentary blood flow
in the periphery.
Vascular functioning is more challenging to quantify at a given point because blood
pressure fluctuates greatly throughout the circulatory system. For instance, BP in the aorta and
large arteries is markedly greater than in the venae cavae and large veins, due to their location
within the circulatory system and their ability to distend (Berntson et al., 2007). Oscillometric
blood pressure monitoring (OBP) is a measurement approach that enables peripheral vasculature
to be monitored remotely (Berntson et al., 2007). OBP can provide estimates of systolic, diastolic
and mean arterial pressure (MAP; Berntson et al., 2007; Babbs, 2012).
Extrinsic Control
Extrinsic control of the CVS occurs through interdependent mechanisms in the central
nervous system (CNS), autonomic nervous system (ANS), and HPA axis. The majority of CNS
control is automatic and is housed in primitive brain stem structures including the medulla and
8

cerebellum (Andreassi, 2007; Berntson et al., 2007). Additionally, baroreceptors in the carotid
sinus provide reflexive feedback to these brain structures, increasing HR when blood pressure
decreases. These lower-level mechanisms give rise to higher-level central and autonomic control
(Berntson & Cacioppo, 2007; Berntson et al., 2007).
Synergistic coactivation of the HPA axis and the ANS provides much of the extrinsic
control for the CVS. Hormonal substrates initiate activity along the two branches of the ANS,
providing electrochemical impulses for local alterations in muscle and tissue (Andreassi, 2007;
Berntson & Cacioppo, 2007; Berntson et al., 2007). The sympathetic nervous system (SNS)
maximizes blood flow to large muscle groups, constricts peripheral vasculature, and increases
cardiac output, thereby energizing the body. The parasympathetic nervous system (PNS) opens
channels of blood flow, dilates peripheral vasculature, and slows heart rate (HR) and respiration,
thereby conserving energy.
Hormonal facilitation in the CVS is important because it provides impetus for SNS and
PNS projections to alter heart rate (chronotropic effects; primarily related to PNS activation),
muscle contractility (inotropic effects; primarily related to SNS activation) and peripheral
vasoconstriction (also sympathetically moderated). The speed of SNS and PNS effects are
considerably different (Berntson et al., 1997; Berntson et al., 2007). PNS activation can produce
significant chronotropic effects almost immediately, whereas SNS activation has a longer, more
cumulative impact on cardiovascular function (Andreassi, 2007, Somsen et al., 2004).
Accordingly, the SNS and PNS play a central role in determining how the CVS adapts (or fails to
adapt) to demands placed upon it. This process is known as cardiac autonomic control (CAC).
Empirical evidence suggests that dysregulated CAC within these branches may place an
9

individual at risk for health complications (Chang et al., 2010; Hemmingway et al., 2005;
Lambert et al., 2010; Masuo et al., 1997). One explanation for this relationship lies in the
physiological stress response.
Physiological Stress Response
Selye (1956) described stress as a physical state that manifests via stereotypic responses
in the face of a particular demand on the body. This definition highlights two important elements
of the stress construct. First, stress is not a discrete external condition, but rather an internal state
that arises in context of external demands (i.e., stressors). Second, the body’s response is
stereotypic; it has a predictable and consistent temporal sequence when triggered.
Biological Self-Regulation
In the presence of internal or external demands, activity across body systems fluctuates to
maintain homeostasis (i.e., equilibrium around a particular set point). This process was referred
to initially as homeostatic regulation (Berntson & Cacioppo, 2007). Cannon (1939) formulated a
number of initial concepts related to autonomic processes in homeostatic regulation that have
had a lasting impact on the understanding of physiological stress response. Namely, that
regulatory effects of the SNS and PNS are balanced (Wenger, 1941), reflexive (Randall,
Wurster, Randal, & Xi-Moy, 1996), and characterized by reciprocal central control (Berntson &
Cacioppo, 2007). Seyle (1973) refined the conceptualization of this process by suggesting that
the regulatory level is necessarily flexible to compensate for changing demands. The term
allostasis or allodynamic regulation (Sterling & Eyer, 1988) encompasses the notion that
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stability must be achieved through change and reflects the finding that autonomic regulation of
the body is subject to constantly changing internal and external criteria (Dworkin, 1993).
Autonomic Space
Consistent with broad models of biological self-regulation, early conceptualizations of
autonomic regulation also held that SNS and PNS activity was reciprocal, existing along a
continuum from sympathetic to parasympathetic dominance. Findings pertaining to this
continuum support the notion that SNS activation occurred with PNS inhibition, and vice versa
(Malliani, 1999).
However, other empirical investigations revealed differences in the specific modes of
ANS activation during times of stress (Iwata & LeDoux, 1988; Koizumi & Kollai, 1981; Quigley
& Berntson, 1990). These findings suggested separation of SNS and PNS activity that appeared
to override tendencies toward reciprocity. In turn, Berntson and colleagues (Berntson, Cacciopo
& Quigley, 1991; 1993a; Berntson, Cacciopo, Quigley & Fabro, 1994) formulated the doctrine
of autonomic space, which accounts for fluidity in autonomic activation. This model holds that
ANS activity is best understood within orthogonal two-dimensional space enabling SNS and
PNS activation to be reciprocal, coactive, or uncoupled (see Table 2).
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Table 2. A Matrix Depicting Modes of Autonomic Control
Parasympathetic Response
Sympathetic
Response
Increase

No Change

Decrease

Increase

No Change

Decrease

Coactivation

Uncoupled sympathetic
activation

Reciprocal sympathetic
activation

Uncoupled
parasympathetic
activation

Baseline

Uncoupled
parasympathetic
withdrawal

Reciprocal
parasympathetic
activation

Uncoupled sympathetic
withdrawal

Coinhibition

In support of this model, Bernston, Norman, Lawkley, and Cacioppo (2008) provide
evidence that cardiovascular changes related to autonomic control reflect multiple configurations
of SNS and PNS activity. The research team collected numerous CVS measures from a sample
of 229 adult participants in the community during a three-year epoch of the Chicago Health,
Aging, and Social Relations Study. The team used data from ECG and ICG recordings to derive
measures of CAC (see Figure 3), which they labeled cardiac autonomic balance (CAB; based on
SNS and PNS reciprocity) and cardiac autonomic regulation (CAR; based on SNS and PNS coactivity).
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Figure 3. Relationship Between CAB and CAR within the Doctrine of Autonomic Space.
The team compared these and other markers of SNS and PNS activity (e.g., HR and
HRV) to various subjective and objective health outcomes including DM2, myocardial infarction
(MI), and quality of life. The results further indicated that those with low CAR scores were more
likely to have a history of MI, where as those with low CAB scores were more likely to have a
history of DM2. Moreover, the authors concluded that CAR (but not CAB) was predictive of
global health, physical well-being, and pain as measured through self-report after controlling for
demographic variables. These findings not only support the notion that SNS and PNS activation
may occur in a variety of configurations, but also indicate that each carries implications for
physical health. The findings are also consistent with literature suggesting dysregulated
autonomic activity is associated with chronic illness.
Licht et al. (2010) developed a separate study to demonstrate that CAC has unique
etiological implications for MetS. Working from the doctrine of autonomic space, the authors
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utilized longitudinal data to examine CAC and HPA activity among a cohort of participants in
the Netherlands Study of Depression and Anxiety (NESDA) over a three-year period. The
authors monitored CAB, CAR, and salivary cortisol levels among 1,883 adults who presented
with varying degrees of metabolic risk, ranging from none (0 risk factors) to severe (all 5
factors). The authors then compared response patterns across participants to determine the extent
to which autonomic (as opposed to hormonal) activity relates to metabolic abnormalities. Results
indicated not only that individuals with MetS show lower CAB and CAR, but also that these
variables were linearly related to the number of metabolic abnormalities. The authors determined
that hormonal measures did not have metabolic implications, pointing to the specific effect of
ANS activity in the development of MetS. These findings lend support to the notion that across
individuals, patterns of CAC are related to distinct physical outcomes.
The doctrine of autonomic space offers an effective description of CAC, but does not
clearly explain the ways in which this process can lead to MetS. Furthermore, these studies are
limited by a failure to monitor psychosocial features of the stress response. This limitation is
particularly important because the psychological stress response may help explain the
relationship between CAC and MetS.
Psychological Stress Response
Psychological variables are known to play a crucial role guiding patterns in allodynamic
regulation during times of stress (Berntson & Cacioppo, 1999; Curtis & O’Keefe, 2002;
Jorgensen & Kolodziej, 2007; Lambert et al., 2010). Current theory suggests the extent and
intensity of the stress response is mediated by the psychological response to the stressor. This
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response is commonly labeled appraisal (Lazarus, 1993; Lazarus & Folkman, 1984; Schwartz et
al., 2003).
Appraisal is built upon two complementary processes: primary (or demand) appraisal and
secondary (or resource) appraisal (Blascovich & Mendes, 2000; Blascovich & Tomaka, 1996).
Primary appraisal refers to the judgment of situational danger and/or required effort. Secondary
appraisal refers to the judgment of personal skills or knowledge relevant to performance in light
of the situation (Blascovich & Mendes, 2000). The resolution of the primary-secondary appraisal
process establishes a particular motivational state that leads to cognitive and behavioral
tendencies intended to cope with the stressor.1 This motivational state is highly relevant
physiologically; it ensures the body responds to the external demand in a manner consistent with
primary and secondary appraisals.
The Biopsychosocial Model of Challenge and Threat
Blascovich and colleagues’ biopsychosocial model of challenge and threat (Blascovich,
2008; Blascovich & Mendez, 2000; Blascovich & Tomaka, 1996) outlines how differences in
primary and secondary appraisals underlie specific motivational states and describes how these
states manifest in the body. The model stipulates that in the context of motivated performance

1

A fundamental distinction with regard to coping strategies involves whether the strategy moves
the individual toward (approach) or away (avoidance) from a particular target, object, or goal
(Elliot & Fryer, 2008). It has been suggested that approach-avoidance dichotomy can be mapped
on to the challenge-threat model; however, one particular motivational state does not universally
precede one particular behavioral coping strategy. The concordance between these two concepts
is complicated further by mediating and moderating variables including gender, dispositional
traits, and sociocultural norms. A more accurate parallel concept may be active vs. passive
coping, which relates to the individual’s perceived resources as opposed to objects, targets, or
goals.
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situations (i.e., those that require instrumental cognitive or behavioral performance), an
interaction between affective and cognitive evaluations during the appraisal process determines
whether the individual enters a challenge or threat motivational state (see Figure 4a).
(a)

(b)
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Evaluation
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Figure 4. Blascovich & Colleagues’ (a) Biopsychosocial Model of Challenge and Threat and (b)
Theoretical Cardiovascular Patterns Associated with Each Motivational State.
Note: Adapted from Blascovich & Mendes (2000); PEP = Pre-ejection Period (cardiac
contractility); TPR = Total Peripheral Resistance (vascular response)
Challenge states occur when the available resources are judged to be equivalent to or
outweigh the perceived demand. Threat states occur when situational demands are judged to be
greater than the available resources. The authors theorize that certain variables moderate
processes of demand and resource appraisal including uncertainty, physical and psychological
danger, skills, knowledge and support; they also propose that these states tend to carry hedonic
valance, noting threat is more likely to elicit negative affect.
The authors submit that challenge and threat motivational states are associated with
distinct cardiovascular patterns, consistent with the concept of cardiac-somatic coupling as well
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as previous work by Obrist (1981) and Dienstbier (1989). The model suggests that challenge
states are marked by decreases in total peripheral resistance in conjunction with increased
cardiac output (cardiac-somatic coupling), producing little change in blood pressure. Conversely,
threat states are associated with minimal increases in total peripheral resistance in conjunction
with increased cardiac output (cardiac-somatic uncoupling), which has the effect of increasing
blood pressure (see Figure 4b). This theoretical model gained support through experimental
studies that confirm expected cardiovascular patterns among individuals in challenge and threat
motivational states (Tomaka, Kibler, Blascovich, & Ernst, 1997; Blascovich, Seery, Mugridge,
Norris, & Weisbuch, 2004).
Challenge, Threat, and Illness
Blascovich (2008) suggests that challenge states tend to be adaptive (synchronous cardiac
activation and vasodilation that facilitate effective performance), while threat states tend to be
maladaptive (asynchronous cardiac activation and vasoconstriction that inhibit effective
performance). The initiation of threat states leads to cardiovascular strain in non-metabolically
demanding situations. Therefore, the direct relationship between challenge/threat states and
health is one that can be defined and tested.
Blascovich and Katin (1993) note that vascular contractility in conjunction with increased
cardiac output (i.e., threat state) precipitates blood turbulence within coronary arteries and acute
hypertension. This process can produce lesions in the endothelial lining of these arteries
increasing the likelihood of scarring and arteriosclerosis. In addition, Manuck, Kamarck,
Kasprowicz, and Waldstein (1993) concluded that repeated elevations in blood pressure
consistent with threat states impede intrinsic hemoregulatory mechanisms, potentially
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precipitating clinical hypertension. Indeed, persistent activation of this pattern of appraisal is
associated with an increase in allostatic load (i.e., a systemic failure of regulatory mechanisms
brought on by chronic stress), which leads to heightened baseline activation in body systems
under hormonal and autonomic control (McEwen & Stellar, 1993).
Challenge and threat states can impact physical health in other ways. An intriguing
extension of this model yet to be tested suggests that particular patterns of PNS and SNS
activation along with the cardiovascular profiles of challenge and threat states create an indirect
line of influence on MetS by attenuating health behavior and treatment adherence. Treatment
non-adherence is related strongly to increased disease progression, particularly in CVD and DM2
(Asche, LaFleur & Conner, 2011; Bodenheimer, Lorig, Holman & Grumbach, 2002; DunbarJacob & Mortimer-Stephens 2001; Gonzalez et al., 2008; Lerman, 2005). It is possible that
perceiving insufficient resources in motivated performance situations both (1) increases negative
affect (e.g., worry, fear, depression; Blascovich & Mendes, 2000) and (2) inhibits tendencies
toward health behavior and/or adhering to treatment recommendations, thereby minimizing
illness-based stress. Indeed, theories of treatment adherence such as the Health Compliance
Model-II (HCM-II; Heiby & Frank, 2003) suggest motivational state and emotional experience
are chief determinants of treatment adherence and health behavior (Heiby & Lukens, 2006).

18

The Proposed Investigation: Aims and Hypotheses
Based on current literature and unresolved questions, we have developed four study aims
and corresponding hypotheses.
Table 3. Study Aims and Hypotheses.
Aim
1

Validate the relationship between CAC and MetS
H1

2

Consistent with findings from Berntson et al. (2008), both CAB and CAR will
predict concurrent diagnosis of DM2 and CVD. CAC will be positively related
to self-reported well-being and negatively related to depression and anxiety.
H2
Patients with metabolic syndrome will evidence lower baseline CAB & CAR
scores.
Examine the patterns of CAC among patients with MetS during a standardized
stressor.
H3

3

Patients with metabolic syndrome will evidence lower CAB & CAR scores
during standardized stressors.
Examine the patterns of CAC among individuals with MetS during a health and
wellness interview.
H4

4

Patients with metabolic syndrome will evidence lower CAB & CAR scores
during the health and wellness interview.
H5
During the experimental tasks, responding with a cardiovascular “threat”
configuration will be associated with MetS.
Examine the influence of cardiac autonomic control on health behaviors &
treatment adherence among individuals with MetS.
H6

Low CAB & CAR scores will be associated with increased BMI, decreased
physical activity, increased smoking behavior, increased drinking, and
decreased self-reported medication adherence.
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CHAPTER TWO: METHODOLOGY
Participants
Participants were 51 primary care patients at the University of Central Florida Health
Clinic (UCFH) who were identified as study candidates by having any number of metabolic
abnormalities consistent with NHLBI guidelines. Within this full sample, 25 individuals met
diagnostic criteria for MetS as confirmed by their referring physician, and 26 individuals were
identified as “healthy controls” (HC; presented with two or fewer metabolic abnormalities). One
individual in the HC group was removed form the initial sample due to failure of the ambulatory
monitoring device. The final sample (N=50) was predominantly female (68%) with a mean age
of 56.32 years (SD=16.74). The majority of the final sample identified as Caucasian (64%) with
a smaller proportion identifying as Latino/a (16%), Black/African American (12%) and Asian
(8%). Table 4 (see Results section, below) provides more specific information about the final
sample, including demographic and medical characteristics of each of the experimental groups as
well as analysis of group differences along these characteristics.
Measures
Metabolic Syndrome
The NHLBI guidelines (Grundy et al., 2006) stipulate that three of five risk factors must
be present for diagnosis of MetS (see Table 1). These criteria have been adjusted from previous
guidelines to reconcile differences in interpretive ranges and the complication of frequently
prescribed medications targeting metabolic abnormalities. Assessment of these abnormalities
were be conducted through measurement of waist circumference in the case of risk factor 1, and
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using current medical records, laboratory tests, and vital signs in the case of factors 2-5.
Following diagnostic guidelines, waist circumference was measured using a measuring tape
placed around the abdomen on a horizontal plane (parallel to the floor) at the level of the iliac
crest. The research team consulted medical records, laboratory tests, vital signs, and medication
prescription records to confirm the existence of metabolic risk factors.
Cardiac Autonomic Control
Accurate and reliable measurement of CAC necessitates an ensemble of measures that
include ECG, ICG and OBP. We utilized ambulatory measurement for each of these signals.
Participants were seated for all data collection procedures.
ECG and ICG
ECG and ICG were recorded simultaneously using a series of adhesive sensors affixed to
the participant’s skin. ECG was recorded using two Ag/AgCl spot electrodes in standard Lead-II
configuration. The typical reference, or “ground,” electrode in ECG monitoring was assigned to
one of the ICG electrodes. ICG was recorded using four Ag/AgCl adhesive spot electrodes
placed in corresponding dorsal and ventral sites (see Figure 5). These sensors were connected via
touchproof snap leads to an ambulatory monitoring device (MindWare Mobile) provided by
MindWare Technologies (Gahannah, OH). Offline, data were subjected to a band pass and notch
filters to remove movement and electrical (60 Hz) artifact, respectively. All data collection and
analysis procedures followed best practice guidelines (Berntson et al., 1997; Sherwood et al.,
1990).
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Figure 5. Sensor Placement and Electrical Configuration (+/-) for ECG and ICG Recording.
Note: Subscripts indicate lead number. G = Ground, omitted in this investigation.
Analysis of the ECG waveform produces estimates of HR and HRV. HR is defined as the
average number of beats over a period of time (e.g., beats per minute) measured using a count of
R waves observed in that period. In contrast, HRV is defined as the variability in the inter-beat
interval (IBI) between R waves measured using either time or frequency domains. The frequency
domain (expressed in Hz) is most appropriate for assessing changes over shorter periods of time
(Berntson et al., 1993b). HRV requires a minimum of number of breath cycles (typically 10),
which takes between 30 seconds and 60 seconds for most individuals. This method produces two
main frequency ‘bands’ that represent differing levels of autonomic control.2 The low-frequency
band (LF; 0.05-0.15 Hz) is associated with combined sympathetic and parasympathetic
influences (coactivation), whereas the high-frequency band (HF; 0.15-0.4 Hz) is associated with
parasympathetic control of the heart (Berntson et al., 1997). The HF band is the metric of an

2

A third band exists at the very low-frequency range (VLF; 0.003-0.05 Hz), which represents
primarily thermoregulatory mechanisms associated with circadian rhythm (Berntson et al.,
1993b, 1997)
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chronotropic phenomenon called respiratory sinus arrhythmia (RSA), a feature of independent
parasympathetic control of the heart.
ICG necessitates ECG (Berntson et al., 2007, Sherwood, 1993). The Q and R waves in
the ECG signal establish cardiac landmarks that can be fitted to the two ICG waveforms, Z0
(basal thoracic impedance) and dZ/dt (1st derivative of Z0). Figure 6 presents prototypical
examples of ICG waveforms as they relate to the QRS complex.

Figure 6. Relationships Among ECG and ICG Signals and Corresponding Landmarks
Note: PEP = Pre-ejection Period; LVET = Left Ventricular Ejection Time; Adapted from
Berntson et al. (2007).
There are two landmark points in the dZ/dt signal (i.e., B and X points) from which
physiological cardiac function can be derived. The B point is located at the primary inflection in
the waveform marking ventricular ejection (Lozano et al., 2007). Pre-ejection period (PEP) is
calculated as the time between Q onset and the B point. The X peak is the lowest point in the
dZ/dt signal and marks closure of the aortic valve and the end of ventricular ejection. Left
ventricular ejection time (LVET) is calculated as the time between the B and X points. Both PEP
and LVET are indices of cardiac contractility and thus relate to sympathetic control.
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In the present study, RSA and PEP were used to calculate indices of CAB and CAR as
defined by Berntson et al. (2008). Specifically, the CAB dimension is quantified as the
difference between normalized (z-score transformed) indices of SNS and PNS activation at a
given point in time, such that CAB = zHF – [(-1)zPEP]. Conversely, the CAR dimension is
quantified as the sum of normalized indices of SNS and PNS activation at a given point in time,
such that CAR = zHF + [(-1)zPEP]. In these calculations, normalization is required due to
scaling differences between these measures. Inversion of PEP is required due to the negative
correlation between this measure and SNS activity. Although CAB and CAR enable delineation
of SNS and PNS reactivity, a more fine-grained method for measuring SNS responses is
warranted due to the mounting evidence for SNS dysregulation in MetS (e.g., Licht et al., 2013).
Oscillometric Blood Pressure (OBP)
While measures of cardiac reactivity are available from ECG and ICG, measures of
vascular reactivity can only be obtained by recording peripheral BP. Peripheral PB was recorded
oscillometrically using an Oscar 2 Ambulatory Blood Pressure Monitor provided by SunTech
Medical (Morrisville, NC). This technique records pressure oscillations in an inflated pneumatic
cuff produced by a depressed artery (Babbs, 2012). An adjustable, inflatable nylon cuff was
placed around the patient’s left upper arm at the level of the heart. OPB was measured once at
baseline and at 5-minute intervals through out the experimental procedure. The Oscar 2 device
automatically monitors and calculates systolic (SBP) and diastolic blood pressure (DBP), from
which mean arterial pressure (MAP) and total peripheral resistance (TPR) can be determined.
MAP is calculated from systolic and diastolic estimates such that MAP = 2(DBP/3) + SBP/3.
TPR is calculated as the quotient of MAP and cardiac output (Berntson et al., 2007).
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Health Measures
Psychosocial Health
Anxiety and Depression
The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) is a 14item measure of anxiety and depression that has been used extensively in medical and primary
care settings. Items on the scale address current physiological and psychological symptoms (e.g.,
I get a sort of frightened feeling like 'butterflies' in the stomach). Respondents provide ratings on
a four-point Likert scale with variable anchors based on the extent to which they have
experienced that symptom within the past week. The instrument contains two subscales of even
length, including anxiety (HADS-A) and depression (HADS-D). Raw scores are summed to
represent normal (0-7) borderline abnormal (8-10) and abnormal (11-21) levels of anxiety and
depression, respectively. The psychometric properties of the HADS have been scrutinized in a
number of populations and have been found to be excellent. Bjelland, Dahl, Haug and
Neckelmann (2002) concluded that the internal consistency of the two subscales are very good to
excellent (HADS-A α = .68-.93, HADS-D α = .67-.90) and that estimates of convergent validity
indicate strong positive correlations with similar measures (r’s = .49-.83). Sensitivity and
specificity of the instrument were in optimal balance at a score of 8 or above.
Coping Style
The Brief Coping Scale (Brief COPE; Carver, 1997) is a 28-item measure of coping style
that has been used in both stress and health outcome research. Items on the scale represents a
method for coping with life stress (e.g., I've been taking action to try to make the situation
better). Respondents rate the extent to which they use each method on a five-point Likert scale (1
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= I haven’t been doing this at all, 4 = I’ve been doing this a lot). Scoring yields 14 two-item
subscales with higher scores indicating greater use of that strategy. Subscales include Behavioral
Disengagement, Denial, Self-distraction, Self-blame, Substance Abuse, Active Coping, Positive
Reframing, Planning, Humor, Acceptance, Religion, Emotional Support, Instrumental Social
Support, and Venting. No procedure exists for creating second-order composite or factor scores;
however, the author indicates that these scales can be organized within a second-order structure
based on patterns evident in the observed responses. Such efforts have been undertaken in
previous research to identify patterns in passive, active, and avoidant coping (Litman, 2006;
Marroquín, Fontesc, & Scilletta, 2010; Mitchell, MacLeod, & Cassisi, in press). The Brief COPE
has demonstrated adequate to very good internal consistency (all but one subscale   .60) and
test-retest reliability (r’s = .46-.86).
Quality of Life
The World Health Organization Quality of Life – Brief Version (WHOQOL-BREF; The
WHOQOL Group, 1996) is a 26-item quality of life measure in adults that has been implemented
in a variety of settings internationally. It was developed as a short form for the longer 100-item
version. Items on the scale (e.g., To what extent do you feel your life to be meaningful?) address
current level of functioning across four biopsychosocial domains (Physical, Psychological,
Social, Environmental). Respondents provide ratings on a five-point Likert scale with variable
anchors based upon their experience within the previous two weeks. Scoring yields four domain
scores with higher scores indicating higher quality of life in that domain. These scores may then
be standardized using a 0-100 scale for ease of comparison. The WHOWOL-BREF has
demonstrated adequate to very good psychometric properties, with ’s ranging from 0.68 to .82
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across all domains. The discriminant and construct validity have been judged to be very good.
The WHOQOL-BREF is correlated highly with similar measures of quality of life and can
differentiate those with high and low quality of life as defined by independent criteria.
Health Behavior and Treatment Adherence
To account for personal and contextual factors in illness, measurement of health behavior
and treatment adherence is necessary. Measuring health behavior and treatment adherence is
challenging for a number of reasons. First, the nature of medical interventions means the specific
treatment recommendations and needs for each individual will be different. Additionally, the
progression of an illness means treatment recommendations change over time; whereas one line
of treatment may be easy to follow (i.e., early in the progression of an illness), a different line of
treatment may present more extensive challenges. Despite these challenges, several themes in
health behavior and adherence can be reliably quantified throughout one’s treatment. Current
perspectives on measuring treatment adherence underscore the need for multiple methods of
measurement that include combined objective and patient-reported measures (Riekert, 2006;
WHO, 2003).
Body Mass Index
Participant’s body mass index (BMI) was recorded as a marker of relative weight. BMI is
defined as the quotient of mass in kilograms (kg) and height in meters squared (m2). Height and
weight were collected from patient medical records obtained on the day of data collection.
Physical Activity
Participant’s level of physical activity was measured with The International Physical
Activity Questionnaire – Short Form (IPAC-S; Ainsworth et al., 2000). The IPAC is an eight27

item self-report inventory that measures recent patterns in physical activity in a number of
domains (e.g., work, leisure, exercise). Items on the scale include questions that address
frequency of physical activity (e.g., During the last 7 days, on how many days did you do
vigorous physical activities like heavy lifting, digging, aerobics, or fast bicycling?). Scoring
protocol provides both categorical measures across individuals (low, moderate, high activity
individuals) and continuous measures of physical activity across activity intensity (walking,
moderate, vigorous activity). The continuous measures are in the unit of Metabolic Equivalent of
Task-minutes (MET-minutes) per week. MET-minutes are useful to quantify physical activity
because they are standardized to account for the intensity of activity. Higher MET-minute scores
are indicative of greater physical activity. A number of studies support the psychometric
properties of the IPAC-S. Estimates of internal consistency and test-retest reliability of the
categorical outcomes are very good (Spearman’s  = .64-.79) and the measure also correlates
highly with objective measures of physical activity (Craig et al., 2003).
Smoking Status
Participant’s smoking history was assessed by self-report. Smoking behavior was
quantified categorically by status (current smoker, previous smoker, never smoked) and
continuously by a count the number of cigarettes smoked per day for current smokers.
Alcohol Use
Participant’s use of alcohol was assessed with The Alcohol Use Disorders Test (AUDIT;
Saunders, Aasland, Babor, de la Fuente, & Grant, 1993). The AUDIT is a 10-item instrument
developed by the World Health Organization to assess drinking behavior in health care settings.
Items on the scale address frequency, amount and problems in drinking behaviors (e.g., How
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often do you have a drink containing alcohol?). Respondents provide ratings on a five-point
Likert scale with variable anchors based on their typical use of alcohol. The AUDIT yields a
single score ranging from 0 to 40, with higher scores indicating maladaptive alcohol use. The
authors suggest that a score of 8 can be used as a cut-off for problematic drinking. The AUDIT
has demonstrated good internal consistency ( = .62-.78), and very good test-retest reliability (r
= .86).
Medication Adherence
The Morisky Medication-Taking Adherence Scale – Eight Item Version (MMAS-8;
Morisky et al., 2008) is a widely used revised version of an earlier four-item scale used to assess
adherence to medication regimens. Each item on the scale asks the respondent about his or her
typical use of medication (e.g., Over the past two weeks, were there any days when you did not
take your medicine?). Respondents answer either “yes” or “no” to each item. A composite score
of summed positive responses is then calculated. Morisky et al. (2008) report the MMAS-8
demonstrated good internal consistency ( = 0.83) and can discriminate between clinical
outcomes in hypertension (i.e., those who demonstrate BP control, versus those who do not).
Although it was developed originally for hypertensive medication adherence, the MMAS-8 has
been utilized in diabetic populations with similar levels of success (Wang, Lee, Tang, Toh, & Ko
2012). The MMAS-8 has been shown to correlate highly with pharmacy refill rates (KrouselWood et al., 2009).
Procedure
The experimental procedure was developed to take place in the context of a primary care
clinic and included three phases: intake (consent documentation and sensor placement),
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physiological recording (baseline period, two counterbalanced stressor tasks, and recovery
periods following each task), and checkout (sensor removal, self-report assessment, and
debriefing).
Participants were recruited from the patient population at UCFH. Eligible patients were
identified prior to their arrival at the clinic during routine clinical consultations between the
investigator, attending physicians, and medical assistants. This consultation is a standard of
practice for integrated healthcare services. Upon presenting for treatment and completing clinic
check-in procedures, patients were escorted to the examination area where the medical assistant
collected routine medical data (height, weight, vital signs).
At that time, the investigator notified the patient about the study, provided an abridged
study description, and invited the patient to participate. Regardless of the participant’s decision
to participate, the patient’s healthcare appointment progressed as usual. In most cases, patients
interested in participating were scheduled for a follow-up appointment to accommodate
scheduling and availability restrictions.
Phase I: Informed Consent and Preparation
The first element of Phase I was provision of a full description of the study procedures
and potential risks and benefits of participation. This conversation occurred at the time of intake
and included a broad overview of the topic of the study. This conversation did not include
specific information about the study hypotheses. Following this description, participants were
asked to provide their verbal consent to participate. Each participant was assigned a three-digit
number to serve as an anonymous identifier throughout data collection and analysis. Each
participant was randomized to one of two experimental conditions, which determined the order
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in which stressor tasks were administered (see Phase II, below). Random assignment was
completed using an virtual random number generator (www.random.org).
The second element of the intake phase was the preparation of the surface recording sites
for ECG and ICG sensors and the attachment of the OBP cuff. Site preparation included a
thorough cleansing of the skin using an alcohol pad. Next, sensors were placed on the skin and
connected to the MindWareMobile device, which was secured to a belt containing the OBP
monitor. Finally, the OBP cuff was placed around the participant’s arm and the device belt is
secured to the participant’s waist.
Phase II: Physiological Measurement
Physiological measurement began with a habituation period lasting five minutes. This
period facilitated physiological habituation to the experimental environment and stabilization of
physiological signals. The final minute of the habituation was used as a baseline for data
analyses. This approach is generally superior to calculating change scores (Berntson, 2014,
personal communication). The habituation period was tracked with a stopwatch, and start and
end times were recorded using a standardized external timepiece. These times were then
converted to a cumulative run-time to permit synchronization of event markers and signals
collected in the experiential procedure.
Physiological measurements were recorded during two counterbalanced stressor tasks: a
mental arithmetic task and a semi-structured health and wellness interview (see Appendices A
and B, respectively). Counterbalancing of the stressors was used to help attenuate order effects in
physiological activation. The mental arithmetic task involved two standardized procedures (i.e.,
Serial 7s and Mental Multiplication), each of which lasted one minute. In Serial 7s, participants
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were asked to subtract seven from 100 and continue to subtract seven from each subsequent
answer. In Mental Multiplication, participants were asked to multiply three by four and continue
multiplying by three each subsequent answer. In both tasks, the investigator provided corrective
feedback for incorrect answers and the participant was instructed to begin again. The health and
wellness interview comprised five topics including medication adherence, diet, exercise, stress,
and coping strategies. Each topic was discussed for approximately two minutes. The series of
questions in each topic of conversation in this interview was uniform for each participant, but the
specific content of each discussion was different, by necessity. The entire interview task lasted
approximately 10 minutes. A five-minute recovery period followed each stressor task to
encourage physiological signals to stabilize. As with the baseline period, stressor duration was
tracked with a stopwatch, and start and end times were recorded using a standardized external
timepiece.
Phase III: Checkout
Sensor removal was the first element of the checkout phase. The researchers removed the
sensors and provided participants with cleansing wipes to remove any adhesive residue from
their skin. The second element of the checkout phase was collection of self-report measures
administered in paper-and-pencil format. The final element of the checkout phase was debriefing
of the purpose and objectives of the experiment. Participants were provided more specific
information about the research questions and were provided the opportunity to ask questions of
the investigators. All participants received a debriefing form containing an additional written
description and contact information for the research team and university review board.
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Data Examination, Screening and Replacement
The investigator examined the entire data set prior to initiating data analyses in
accordance with recommendations by Tabachnick and Fidell (2013). During this process, it was
discovered that several data points were missing or unavailable for analysis. The majority of
these observations were related to medical data collected from patient records. These
observations generally included measures of blood lipid and/or glucose levels, and were
unavailable because either (1) routine collection of these values were not medically necessary as
determined by the treating physicians, or (2) the values were no longer current (i.e., collected
longer than 2 weeks prior to the visit). In light of these missing values, between-group
comparison of these variables and examination of MetS as a continuous indicator was not
feasible in the present study. The remaining missing data points were identified in self-report
measures. Specifically, 11 cases contained missing values, with 1-7 observations missing per
case (approximately 0.9% of the self-report data). These data, missing at random (MAR), were
estimated and replaced via maximum likelihood (FIML) procedures in Mplus (Version 7.11,
Muthén & Muthén; Los Angeles, California). In Mplus, multiple imputation for a set of variables
with missing values is carried out using Bayesian analysis, creating a full dataset that can be used
in subsequent analyses (Muthén & Muthén, 2012). FIML estimation is the preferred method for
data replacement because it is built upon robust procedures that incorporate casewise likelihood
estimation, thereby reducing standard error values (Enders & Bandalos, 2001).
The resulting data set was then checked visually and statistically for multivariate
normality and for violations of the assumptions of the general linear model. Several of the selfreport independent variables were positively skewed. Specifically, all MET-minute variables and
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the AUDIT total score demonstrated positive skewness, with values of 2.31–5.44. To correct for
these findings, we discarded the continuous scores derived from these measures and relied on
categorical scoring, as described in the Measures section, above. All dependent variables were
observed to be approximately normal (skewness < |1|). Examination of normal Q-Q plots and
residual scatter plots suggested that these variables did not violate the assumptions of the general
linear model.
Physiological Signal Processing
Signals were processed visually and digitally on a desktop computer using MindWare’s
BioLab, ICG, and HRV Analysis software version 3.1.1. Prior to processing, event markers
corresponding to the beginning and end of each of the baseline, recovery, and experimental
periods were inserted manually into the data file. ECG and dZ/dt signals were digitized using a
band pass filter with a low cutoff of .50 Hz and a high cutoff of 45.0 Hz. The Z0 signal was
digitized using a low pass filter with a cutoff of 10 Hz. Data were obtained and recorded by
examining the signal between the start and end event markers inserted via synchronized,
cumulative run-time of each individual’s unique experimental procedure. For the Health and
Wellness task, we utilized data from the full two-minute epoch of each interview segment. For
the Mental Arithmetic task, we utilized data calculated from the one-minute epoch for each
stressor.
With regard to HRV calculation, spectral analysis followed a Hamming windowing
function, with the VLF (.003-.04 Hz), LF (.040-.12 Hz) and HF (.12-.42 Hz) bands pre-set across
all participants. The Z0 signal from ICG recording was used as a respiration signal for all HRV
analysis in order to confirm that respiratory sinus arrhythmia occurred in the appropriate HF
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frequency band. HRV analysis involved assessment of mean R-R peak variability (HF HRV, or
RSA) as well as the standard deviation of normal R-R intervals (SDNN).
With regard to ICG calculation, metrics of Z0 and dZ/dt were calibrated at .10 volts/Ohm
and 1.00 Volts/Ohm/Second, respectively, with a blood resistivity constant of 135. The Q point
calculation method was minimum value of the K-R interval where K=35. LVET windowing
followed the Farmingham method with minimum and maximum offset threshold of 200 and 600
milliseconds, respectively. B-point calculation was executed using the 55% plus a constant of 4
procedure, as recommended by Lozano et al. (2007). Stroke volume was calculated using the
Kubicek method. A 60 Hz notch filter was used during all signal processing procedures.
Initially, signal processing involved removal of movement artifact from the raw ECG
signal. Movement artifact was confirmed through examination of X-, Y-, and Z-axis actigraphy
housed within the mobile monitoring unit. As a component of artifact removal, R-peak accuracy
was assessed and corrected as needed. Upon verification of accurate R-peak placement for all
data segments, automated analyses of HRV and ICG signals were initiated. All output variables
from these automated analyses were then verified manually based on recommendations from
Lozano et al. (2007).
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CHAPTER THREE: RESULTS
Sample Characteristics
Within the final sample, we examined several characteristics of each experimental group
that have the potential to impact physiological performance. These variables were selected on the
basis of theoretical mechanisms underlying physiological performance or because previous
research has indicated that particular variable may have such an effec. Table 4 contains
descriptive and demographic characteristics for the full sample (N=50), stratified by
experimental group. Table 4 also contains between-group comparisons on variables not directly
included in establishment of MetS diagnosis.
Table 4. Sample Characteristics by Experimental Group.
Experimental Group

Mean Age (SD)
Female Sex (N, %)
Race
Caucasian (N, %)
Latino/a (N, %)
Black (N, %)
Asian (N, %)
Mean BMI (SD)
Mean # Medical Problems (SD)
Mean # CV Medications (SD)

Healthy Control
(N=25)

Metabolic Syndrome
(N=25)

F (df)

p

52.04 (18.37)
20, 80%

60.60 (14.00)
14, 56%

3.43 (1,49)
–

.075
–

19, 76%
3, 12%
2, 8%
1, 4%
25.99 (5.17)
5.64 (0.82)
0.32 (0.75)

13, 52%
5, 20%
4, 16%
3, 12%
31.81 (6.60)
9.28 (1.01)
1.28 (0.98)

–
–
–
–
12.09 (1,49)
7.73 (1,49)
15.15 (1,49)

–
–
–
–
.001
.008
<.001

Note: BMI = Body mass index; CV = Cardiovascular
With regard to race, we examined the relative proportions of race within the experimental
groups using chi-square test of independence and found no difference between the HC and MetS
groups, χ2 (3)=3.29, p=.349. With regard to sex, there is considerable evidence that rate of MetS
diagnosis varies by sex and that sex influences patterns of cardiovascular responses (Ordaz &
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Luna, 2012; Stoney, Davis, & Matthews, 1987). As such, we chose to include sex as an
independent between-subjects variable or, unless otherwise noted, as a covariate in analyses
examining either experimental group membership or CV activity. We also controlled for medical
complexity (i.e., number of medical problems) in analyses that examined between-subject
differences. This decision was based on the observed between-group differences, and findings in
the literature that suggest individuals with chronic or advanced medical diagnoses may present
with unique physiological profiles (Manganelli et al., 2002; Wakkee, Thio, Prens Sijbrands, &
Neumann, 2006).
In the process of data collection, we tracked the use of medications known or intented to
alter or adjust CV functioning, including the broad class of antihypertensive medications. The
majority of the sample (52%) were not on any CV medication with smaller proportions
prescribed one (24%), two (16%), and three (12%) CV medications. Table 5 provides an
overview of medication prescription in both the HC and MetS groups.
Table 5. Number of Individuals Prescribed CV Medications by Experimental Group
Experimental Group
Medication
ACE Inhibitors
A2R Blockers
Diuretics
Thiazide
Loop
Aldasterone Blocker

HC
0
3
–
1
0
2

Experimental Group

MetS
7
7
–
6
0
0

Medication
NDH CCB
DH CCB
Beta Blocker
Alpha Blocker
Antiarrythmics
Stimulants

HC
0
0
0
1
0
1

MetS
0
4
5
3
0
0

Note: HC = healthy control; ACE = angiotensin converting enzyme; A2R = angiotensin II
receptor; NDH = non-dihydropyridine; DH = dihydropyridine; CCB = calcium channel blocker
Whereas several of these drugs work primarily on the physiology of the vascular system
(e.g., ACE inhibitors), others work primarily on the heart cycle (e.g., beta blockers). In addition,
several of these medications (e.g., diuretics) bring about systemic changes that comprehensively
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alter the cardiovascular system, making it difficult to control for the global impact of these
various agents. Therefore, in analyses examining either cardiac (e.g., CAB, CAR, PEP), or
vascular functioning (e.g., TPR), we used as covariates only those medications that have direct
cardiac or vascular implications, respectively.
Examination of Study Aims and Tests of Experimental Hypotheses
Aim 1: Validate the Relationship Between CAC and MetS
Hypothesis 1: CAC will predict concurrent medical and mental health concerns
Following Berntson et al. (2008), binary logistic regression was employed to predict
diagnosis of DM2 and CVD from baseline CAB and CAR scores. The DM2 group (N=11)
included all individuals with a current diagnosis. The CVD group (N=9) included all individuals
with recorded diagnosis of coronary artery disease, congestive heart failure, or arrhythmia, as
described by the American Heart Association. Both baseline CAB and CAR scores and an
interaction term (CAB  CAR) were entered into the regression equation in a hierarchical
fashion, with CAB preceding CAR in the prediction of DM2 diagnosis, and CAR preceding
CAB in the prediction of CVD. To avoid multicolinearity, the individual components of the CAB
and CAR variables were not included in these models. Observed groups and predicted
probabilities plots were generated to identify potential outliers; none were detected. Findings
from the final model blocks are described in-text. Findings form the full models are presented in
Table 6.
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Table 6. Full Model Logistic Regression Analysis Predicting Diagnosis of Diabetes and
Cardiovascular Disease from CAB and CAR Scores.
Type 2 Diabetes Diagnosis (N=11)
Predictor
(Constant)
CAB
CAR
CAB  CAR

β

SE β

Wald

df

p

eβ

-1.319
-0.003
0.074
-0.315

0.375
0.226
0.315
0.271

13.646
0.000
0.054
1.354

1
1
1
1

.000
.991
.816
.245

0.267
0.997
1.076
0.730

χ2

df

p

1.505
11.848

3
8

.651
.158

Test
Overall Model Evaluation
H-L Goodness of Fit
Cardiovascular Disease Diagnosis (N=9)
Predictor
(Constant)
CAR
CAB
CAB  CAR

β

SE β

Wald

df

p

eβ

-2.040
-0.786
-0.562
-0.426

0.556
0.388
0.355
0.333

13.451
4.115
2.501
1.633

1
1
1
1

.000
.042
.114
.201

0.130
0.456
0.570
0.653

χ2

df

p

8.275
8.745

3
8

.041
.364

Test
Overall Model Evaluation
H-L Goodness of Fit

Note: H-L = Hosmer-Lemeshow
None of the logistic models predicting diagnosis of Type 2 Diabetes was significant;
however, the final model iteration predicting diagnosis of CVD was significant, Nagelkerke
R2=.250, and correctly classified 86% of all CVD cases. In this model, CAR was a significant
negative indicator (β=-0.562), suggesting decreased CAR scores are associated with an increased
likelihood of being diagnosed with CVD. The Hosmer-Lemeshow goodness-of-fit test was nonsignificant for this model, indicating that this model is appropriately specified, and observed
group membership did not deviate from the expected count predicted by the model. This finding
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is consistent with previous research provided by Berntson and colleagues that indicate
diminished CAR scores are associated with previous MI.
Subsequently, a series of hierarchical linear regression analyses was employed to
determine if CAC variables, including CAB, CAR, and individual measures of the cardiac cycle
predict self-reported quality of life, anxiety and depression scores. We chose to include
individual cardiac measures in the model to account for independent activation of sympathetic
and parasympathetic branches, as CAB and CAR capture reciprocity and co-activation of these
branches, respectively. To account for potential experimental group differences (HC vs. MetS), a
dummy-coded dichotomous variable was entered into the first block of the regression. Baseline
CAB and CAR were included in the second block, and baseline measures of PEP, RSA, LVET,
and CO were included in the final block. Although SV was originally included in the model, it
was removed to avoid multicolinearity. Mahalonobis distances were computed to identify
outliers; none were detected. Table 7 contains descriptive statistics and zero-order Pearson
correlations among all observed variables in this model. Additional descriptive statistics for
study variables are presented in Appendix A.
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Table 7. Descriptive Statistics and Zero-order Correlations Among Physiological and Self-report Health Measures in the Full
Sample.
1

2

1. CAB

–

2. CAR

.00

3

4

5

6

7

8

9

10

-.59***

4. RSA

.81

***

***

5. LVET

-.13

.12

-.17

-.03

–

6. SV

-.14

.08

-.16

-.07

-.50***

7. CO

-.27*

.02

-.23

-.21

.41**

8. ANX

-.26

.05

-.24

-.18

-.10

.09

.12

9. DEP

-.09

-.03

-.06

-.09

-.01

.04

.05

.63***

-.06

-.48

***

-.51***

-.73

***

-.70

***

-.51

***

-.49

***

-.56

***

11. QLPS
12. QLS
13. QLE

.14
.10
.11

13

–

.80

10. QLPH

12

–

***

3. PEP

11

.59

.14
.03
-.05

.29*

.03
.06
.12

–

.19
.09
.06

.11
.07
.09

–
.93***

.06
-.12

–

-.17

-.11

-.18

.26

.00

.21

.21

.20

-.14

-.26

Descriptives

CAB

CAR

PEP

RSA

LVET

SV

CO

Mean

0.00

0.00

92.76

4.86

304.80

257.64

SD

1.61

1.19

24.00

1.15

71.94

Minimum

-3.13

-3.78

50.00

2.66

Maximum

3.85

2.92

142.00

7.58

–
–

-.34

*

–
.59***
.44

**

.47

***

–
.63***
.59

***

–
.65***

–

ANX

DEP

QLPH

QLPS

QLS

QLE

17.85

6.94

4.44

14.33

14.33

13.38

16.04

106.73

7.05

3.55

2.98

3.22

2.84

3.55

2.86

158.00

94.47

6.20

1.00

0.00

7.43

7.33

6.67

9.00

410.00

553.33

37.38

14.00

13.00

20.00

19.33

20.00

20.00

Note: *** < .001; ** < .01; * <.05; CAB = Cardiac Autonomic Balance; CAR = Cardiac Autonomic Control; PEP = pre-ejection
period; RSA = respiratory sinus arrhythmia; LVET = left ventricular ejection time; SV = stroke volume; CO = cardiac output; ANX =
Hospital Anxiety and Depression – Anxiety Scale Score; DEP = Hospital Anxiety and Depression – Depression Scale Score; QL-PH
= WHO Quality of Life–Brief–Physical Domain; QLPS = WHO Quality of Life–Brief–Psychological Domain; QLS = WHO Quality
of Life–Brief –Social Domain; QLE = WHO Quality of Life–Brief–Environmental Domain.
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With regard to quality of life, only one model reached significance. In the prediction of
the Quality of Life-Environment Domain, both LVET (β=0.369) and CO (β=-0.353) significantly
predicted total scores on this subscale, R2=.25, adjusted R2=.14, F(5,44)=2.558, p=.041. These
findings indicate that individuals with longer LVET and lower CO scored higher in this domain
of QOL. Models predicting Physical Domain scores, F(5,44)=1.097, p=.375, Psychological
Domain scores, F(5,44)=0.988, p=.436, and Social Domain scores, F(5,44)=1.676, p=.160 failed
to reach significance. These findings indicate that the CAB, CAR, and individual measures of
cardiac functioning did not predict these quality of life domains, while controlling for diagnosis
of MetS.
Regression models predicting anxiety, F(5,44)=1.056, p=.728, and depression,
F(5,44)=0.674, p=.645, failed to reach significance. These findings indicate that the CAB, CAR,
and individual measures of cardiac functioning did not predict these self-reported anxiety or
depression scores, while controlling for diagnosis of MetS. Collectively, these results provide
only partial support to our first experimental hypothesis.
Hypothesis 2: Individuals with MetS will evidence lower CAC at baseline
Prior to examination of baseline CAB and CAR, we performed a 2 (experimental group)
 2 (sex) multivariate analysis of covariance (MANCOVA) to determine differences in baseline
PEP and RSA. We controlled for number of medical problems and for medication use by
entering as a dummy-coded variable patients who were and were not prescribed beta-blockers. In
reviewing multivariate results, we failed to detect main effects for group, Λ=.958, F(2,
43)=0.933, p=.401, or sex, Λ=.991, F(2, 43)=0.189, p=.828, suggesting that neither baseline PEP
nor RSA were significantly different between these sets of participants.
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Subsequently, we performed a 2 (experimental group)  2 (sex) MANCOVA to identify
differences in baseline CAB and CAR scores. We controlled statistically for baseline PEP and
RSA scores as well as number of medical problems and medication use, as noted above. We
failed to detect main effects for group, Λ=.979, F(2, 43)=0.464, p=0.632, or sex, Λ=.993, F(2,
43)=0.153, p=.859, suggesting that neither baseline CAB nor baseline CAR scores were
significantly different between these groups, even when controlling statistically for medical
problems and medication use. These findings do not support experimental hypothesis 2.
Aim 2: Examine CAC among patients with MetS during a standardized stressor.
Hypothesis 3: Patients with MetS will display lower CAC scores during standardized stressors.
Prior to examining group differences in calculated CAC scores during any of the
experimental stressors, our first task was to verify that group differences exist in the constituent
variables that comprise the computed CAB and CAR scores. These analyses also helped us
verify the effectiveness of our experimental manipulation. To this end, we executed pairedsample t-tests across the full sample to examine differences in PEP and RSA between baseline
and each segment of the experimental manipulation. We also conducted a 2 (experimental group)
 2 (sex) MANCOVA to determine differences in PEP and RSA scores during both the mental
arithmetic and health and wellness stressors. In the MANCOVA analysis, we controlled for
number of medical problems and medication use by entering as a dummy-coded variable patients
who were and were not prescribed beta-blockers. We also included baseline PEP and RSA scores
as covariates during examination of experimental stressors, following Bernston et al. (2008).
Descriptive statistics for variables included in these analyses are presented in Appendix A.
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Findings from paired-sample t-tests suggested that across the full sample, our
experimental manipulations were associated with significantly lower PEP values relative to
baseline, providing evidence that our experimental manipulation was effective in eliciting a
physiological stress response (see Table 8).
Table 8. Tests of Differences in PEP and RSA Between Baseline and Experimental Task
Segments Across the Full Sample (N = 50).
Health and Wellness Interview
Medication Segment
Baseline – Task Δ PEP
Baseline – Task Δ RSA
Diet Segment
Baseline – Task Δ PEP
Baseline – Task Δ RSA
Exercise Segment
Baseline – Task Δ PEP
Baseline – Task Δ RSA
Stress Segment
Baseline – Task Δ PEP
Baseline – Task Δ RSA
Coping Segment
Baseline – Task Δ PEP
Baseline – Task Δ RSA
Mental Arithmetic
Serial 7s Segment
Baseline – Task Δ PEP
Baseline – Task Δ RSA
Multiplication Segment
Baseline – Task Δ PEP
Baseline – Task Δ RSA

t

df

p

2.216
-1.193

49
49

.031
.239

3.314
-1.087

49
49

.002
.282

1.436
-0.494

49
49

.157
.632

1.866
-0.693

49
49

.068
.492

1.770
0.140

49
49

.083
.889

2.393
1.946

49
49

.021
.057

2.665
0.580

49
49

.010
.565

Note: PEP = Pre-ejection period; RSA = Respiratory sinus arrhythmia
Multivariate results by experimental group revealed a significant main effect for group,
Λ=.469, F(14, 29)=2.348, p=.025, partial η2=.531, but not for sex, Λ=.624, F(14, 30)=1.250, p =
.295. Findings from planned comparisons within this set of analyses are presented in Table 9.
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Table 9. Tests of Between-subject Differences in PEP and RSA During Individual Segments of
the Experimental Task.
Health and Wellness Interview
Medication Segment
PEP
RSA
Diet Segment
PEP
RSA
Exercise Segment
PEP
RSA
Stress Segment
PEP
RSA
Coping Segment
PEP
RSA
Mental Arithmetic
Serial 7s Segment
PEP
RSA
Multiplication Segment
PEP
RSA

F

df

p

Partial η2

6.763
1.011

1, 42
1, 42

.013
.320

.139
.024

8.562
0.102

1, 42
1, 42

.006
.751

.169
.002

0.333
1.137

1, 42
1, 42

.567
.292

.008
.026

0.919
3.591

1, 42
1, 42

.343
.065

.021
.079

0.187
0.061

1, 42
1, 42

.668
.806

.004
.001

0.000
0.636

1, 42
1, 42

.984
.481

.000
.012

0.147
0.871

1, 42
1, 42

.704
.356

.003
.020

Note: PEP = Pre-ejection period; TPR = Total peripheral resistance
After accounting for covariates described above, estimated marginal mean PEP values in
the HC group were higher during the medication and diet segments, as compared to the MetS
group, suggesting a greater sympathetic response in MetS during these segments. The group-bysex interaction failed to reach significance, Λ=.614, F(14, 29)=1.301, p=.263.
We then performed a 2 (experimental group)  2 (sex) repeated measures MANCOVA
to determine differences in CAB and CAR scores during the two mental arithmetic stressors. We
controlled statistically for baseline CAB and CAR scores as well as number of medical problems
and beta-blocker medication (dummy coded). We failed to detect main effects for group,
Λ=.981, F(2, 41)=0.392, p=.678, or sex, Λ=.984, F(2, 41)=0.337, p=.716, suggesting that
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contrary to our hypothesis, CAB and CAR scores during all segments of the standardized
stressor tasks did not differ by experimental group or as a function of sex, when controlling for
medication. Figure 7 depicts group CAB and CAR scores during the mental arithmetic stressors.
0.3
Control

CAC Score (z-tranformed)

0.25

MetS

0.2
0.15
0.1
0.05
0
-0.05
-0.1
-0.15

Serieal 7

Mental Arithmetic
CAB

Serieal 7

Mental Arithmetic
CAR

Figure 7. Between-group Estimated Marginal Means of CAB and CAR Scores During the
Mental Arithmetic Stressors

Aim 3: Examine CAC Among Patients with MetS During a Health and Wellness Interview
Hypothesis 4: Patients with MetS will display lower CAC scores during health interview.
We performed a 2 (experimental group)  2 (sex) MANCOVA to determine differences
in CAB and CAR scores during the five health and wellness interview segments. We controlled
statistically for baseline CAB and CAR scores as well as number of medical problems and
medication use (dummy-coded), as noted above. Overall, we failed to detect main effects for
group, Λ=.931, F(2, 42)=1.561, p=.222, or sex, Λ=.928, F(2, 42)=1.634, p=.207, suggesting that
the CAB and CAR were statistically equivalent across experimental group and participant sex,
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even when controlling for medication use that has the potential to alter sympathetic cardiac
control. Nonetheless, we did detect a segment-by-group interaction, Λ=.496, F(2, 42)=4.573,
p=.001, partial η2=.504, suggesting CAC scores during interview segments differed as a function
of experimental group.
Follow-up multivariate tests of within-subjects effects confirmed this interaction,
Λ=.893, F(8, 334)=2.440, p=.004, and univariate tests of within-subjects contrasts (i.e., changes
over time) revealed that CAB scores across the HWI interview segments were significantly
different between the MetS group and the HC group, F(1, 42)=11.974, p=.001, partial η2=.222.
In addition, we found that CAR scores across the HWI interview segments were significantly
different between the MetS group and the HC group, F(1, 42)=9.495, p = .004, partial η2=.184.
Collectively, this pattern of findings permitted additional inspection of differences in CAB and
CAR at each individual segment.
Planned between-subjects comparisons (paired-samples t-tests corrected for multiple
comparisons using the Bonferoni adjustment) across interview segments confirmed that CAB
scores during the stress segment were significantly higher in the HC group as compared to the
MetS group, p=.049. We also observed that CAR scores during the medication segment were
significantly higher in the MetS group as compared to the HC group, p=.051. MetS and HC
groups did not respond differently during other interview segments, providing partial support for
this hypothesis. Figures 8a and 8b depict CAB and CAR scores, respectively, across each of the
health and wellness interview segments as a function of experimental group.
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(a)

CAB Score (z-transformed)

0.6

**

0.5

Control
MetS

0.4
0.3
0.2
0.1
0
-0.1
-0.2
-0.3
-0.4

Medication

Diet

Exercise

Stress

Coping

Health and Wellness Interview Segment
(b)
0.6
Control

CAR Score (z-transformed)

0.5
0.4
0.3

MetS

**

0.2
0.1
0
-0.1
-0.2
-0.3
-0.4

Medication

Diet

Exercise

Stress

Coping

Health and Wellness Interview Segment
Figure 8. Between-group Estimated Marginal Means of (a) CAB and (b) CAR Scores Across All
Health and Wellness Interview Segments.
Note: ** p < .05
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Hypothesis 5: During experimental tasks, a CV “threat” response will be associated with MetS.
Binary logistic regression was used to predict MetS diagnosis from CV variables.
Unanticipated discrepancies in the initiation of the Mental Arithmetic and Health and Wellness
Interview tasks across participants limited our ability to verify that a particular BP measurement
and TPR value was representative of physiological reactions to that task. Therefore, we used
sequential points of measurement as an alternative method of estimation, serving as a proxy for
on-going task engagement. We entered PEP, TPR, and an interaction term (PEP  TPR)
hierarchically in blocks representing each of the measurement points, such that each block only
contained the observed variables for that point in time (i.e., 300 [baseline], 600, 900, 1200, 1500
and 1800 seconds). The interaction term was intended to depict the simultaneous cardiac and
vascular changes that characterize the “threat” response. In the initial block, we also included
dummy-coded variables accounting for medication prescriptions (beta-blocker and ACE
inhibitor). Each block in the model included previous blocks to estimate the cumulative effect of
these observations in the prediction of MetS.
Table 10. Omnibus Chi-Square, Goodness-of-fit, and Classification Accuracy Derived from the
Full Logistical Model Predicting Metabolic Syndrome through PEP and TPR.
Nagelkerke R2
% correct
χ2
df
p
Block 1, Omnibus Model Test
H-L Goodness-of-Fit
Block 2, Omnibus Model Test
H-L Goodness-of-Fit
Block 3, Omnibus Model Test
H-L Goodness-of-Fit
Block 4, Omnibus Model Test
H-L Goodness-of-Fit
Block 5, Omnibus Model Test
H-L Goodness-of-Fit
Block 6, Omnibus Model Test
H-L Goodness-of-Fit

.000

52.4

.225

54.8

.457

78.6

.538

78.6

.594

83.3

.804

92.9

Note: H-L = Hosmer-Lemeshow
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.008
10.556
7.730
6.558
17.631
8.682
21.665
5.962
24.746
10.155
38.747
3.110

3
8
6
8
9
8
12
8
15
8
18
8

.998
.228
.258
.585
.040
.370
.041
.651
.053
.254
.003
.927

Table 10 provides omnibus chi-square model tests as well as goodness-of-fit tests for
each block in the model. Table 11 provides parameter estimates of all indicators entered into the
full model.
Table 11. Logistical Regression Parameter Estimates, Standard Errors, and Odds Ratio for the
Full Logistical Model in the Prediction of Metabolic Syndrome from Measures of PEP and TPR.

Null Model (Constant)
Block 1 (Baseline)
PEP, 300 seconds
TPR, 300 seconds
PEP  TPR 300 seconds
Block 2
PEP, 600 seconds
TPR, 600 seconds
PEP  TPR 600 seconds
Block 3
PEP, 900 seconds
TPR, 900 seconds
PEP  TPR 900 seconds
Block 4
PEP, 1200 seconds
TPR, 1200 seconds
PEP  TPR 1200 seconds
Block 5
PEP, 1500 seconds
TPR, 1500 seconds
PEP  TPR 1500 seconds
Block 6
PEP, 1800 seconds
TPR, 1800 seconds
PEP  TPR 1800 seconds

β

SE β

Wald

df

p

eβ

22.231

30.890

0.518

1

.472

4.516

0.241
-0.291
-0.054

0.290
4.067
0.045

0.687
0.005
1.464

1
1
1

.407
.943
.226

1.272
.748
.947

-1.209
-6.414
0.166

0.678
5.643
0.109

3.179
1.292
2.350

1
1
1

.075
.256
.125

.298
.002
1.181

-0.761
-14.564
0.168

0.490
8.527
.099

2.241
2.917
2.846

1
1
1

.120
.088
.092

.467
.000
1.183

-0.871
-9.001
0.103

0.657
8.763
0.116

1.760
1.055
0.779

1
1
1

.185
.304
.377

.418
.000
1.108

0.414
-7.018
0.077

0.329
4.486
0.049

1.586
2.448
2.455

1
1
1

.208
.118
.117

1.513
.001
1.080

1.859
29.617
-0.353

1.067
16.870
0.205

3.034
3.082
2.977

1
1
1

.082
.079
.084

6.416
7.285
.702

Note: PEP = Pre-ejection Period; TPR = Total Peripheral Resistance
Overall model chi-square tests reached significance, suggesting that the full model
predicted diagnosis of MetS. Nonetheless, when individual indicators were examined, none of
the Wald estimates in this model reached significance and therefore cannot be interpreted. This
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pattern suggests that no single indicator variable significantly contributed to the full model, but
that collectively, this series of variables adequately predicted group membership.
The independent variables in this analysis were intended to serve as indicators of the
“threat” response. Because they failed to reach significance, the interpretation of this model is
not feasible. As such, an alternative method to understand the association between MetS and
cardiovascular responses involves visual and statistical examination of group differences in PEP
and TPR change scores at each point of measurement. To this end, we compared the
experimental groups on change-from-baseline PEP and TPR at each point of measurement using
2 (experimental group) X 2 (sex) repeated measures MANCOVA controlling number of medical
problems and medication use (beta blocker, ACE inhibitor). Time points were used as the withinsubjects factor in the same fashion as noted above (i.e., at 600, 900, 1200, 1500 and 1800
seconds). The 300-second point of measurement of PEP and TPR was used in the calculation of
change scores and therefore was not included in the analysis.
Contrary to expectations, findings from the MANCOVAs did not reveal a within-subjects
main effect for group, Λ=.965, F(2, 31)=0.561, p=.357. The main effect for sex was also nonsignificant, Λ=.936, F(2, 31)=1.066, p=.278. There was no within-subject main effect for
measurement point, Λ=.804, F(8, 25)=0.761 p=.639, and neither the time-by-group interaction,
Λ=.661, F(8, 25)=1.604, p=.174, nor the time-by-sex interaction reached significance, Λ=.719,
F(2, 28)=1.223, p=.326. Collectively, these findings do not support our fifth experimental
hypothesis.
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Aim 4: Examine the Impact of CAC on Health Behavior and Treatment Adherence
Hypothesis 6: CAC scores will be associated with health behavior and medication adherence
Prior to analyses, we examined the self-report outcome variables to address concerns
related to violations of the general linear model, as described above. We determined that even
when utilizing the well-supported AUDIT cut off score of ‘8’ to denote problematic drinking,
cell size of the problematic drinking group was too small (N = 4) to analyze statistically. In
conjunction with the significant skewness observed in the continuous AUDIT score, we removed
this variable from the analytic plan. Additionally, we created a dichotomous variable from the
physical activity group assignment due to initial findings revealing singularities in the
multinomial regression Hessian matrix, typically indicating statistical separation in the DV.
Separation is sometimes referred to as ‘perfect prediction,’ and occurs when one of the
categorical outcome groups is explained entirely by one level of an indicator variable. In this
case, the recommended approach is to re-specify the model by merging categories of the
outcome variable or creating fewer groups (Gill & King, 2003). Because the groups were
approximately equal in size, we created a dichotomous (median-split) variable based on the
continuous physical activity scale, resulting in low- and high-activity groups. Finally, as
described in the AUDIT scores, we found similar differences in smoking classification, with
separate groups of current smokers (N = 5) and previous smokers (N = 11) creating too few cases
in each cell for analysis. In this case, we collapsed responses to the smoking status question
creating two groups, one comprising current and previous smokers and one comprising nonsmokers.
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We then performed a series of logistic regression analyses predicting smoking group (yes
vs. no) and activity group (low vs. high) using sex and experimental group as initial covariates in
block 1. Both baseline CAB and CAR as well as a CAB  CAR interaction term scores were
entered into the regression equation in a hierarchical fashion in block 2. Subsequently, we
performed a series of linear regressions predicting BMI and medication adherence score using
sex and experimental group as initial covariates in block 1. As above, baseline CAB and CAR
and a CAB  CAR interaction term were entered into the regression equation in block 2.
Findings from the final model blocks are described in-text. Findings form the full models are
presented in Tables 12 and 13.
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Table 12. Full Model Logistic Regression Analysis Predicting Smoking Status and Low Physical
Activity from CAB and CAR Scores
Positive Smoking Status (N=16)
Indicator
(Constant)
Sex
Group
CAB
CAR
CAB  CAR

β

SE β

Wald

df

p

eβ

0.199
-2.114
0.421
-0.305
-0.687
-0.041

0.753
0.780
0.783
0.272
0.356
0.307

.070
7.175
0.289
1.259
3.730
0.018

1
1
1
1
1
1

.791
.007
.591
.262
.053
.894

1.221
.121
1.524
.737
.503
.960

χ2

df

p

15.671
6.799

5
8

.008
.558

Test
Overall Model Evaluation
H-L Goodness of Fit
Low Physical Activity (N=25)
Indicator
(Constant)
Sex
Group
CAB
CAR
CAB  CAR

β

SE β

Wald

df

p

eβ

0.545
-0.250
-0.756
-0.295
-0.083
0.071

0.671
0.663
0.620
0.195
0.264
0.223

0.661
0.142
1.483
2.279
0.100
0.101

1
1
1
1
1
1

.416
.707
.223
.131
.752
.751

1.725
.779
.470
.745
.920
1.073

χ2

df

p

4.704
8.498

5
8

.448
.386

Test
Overall Model Evaluation
H-L Goodness of Fit

The full logistic model predicting physical activity failed to reach significance; however,
as noted in Table 11, the full model predicting smoking status was significant, Nagelkerke
R2=.269, and correctly classified 78% of all cases with affirmative smoking status. In this model,
both participant sex (β=-2.114) and CAR (β=-0.687) were significant negative indicators,
suggesting male gender and decreased CAR scores are associated with an increased likelihood of
smoking status. The Hosmer-Lemeshow goodness-of-fit test was non-significant for this model,
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indicating that this model is appropriately specified, and observed group membership did not
deviate from the expected count predicted by the model.
Table 13. Multiple Regression Estimates Predicting BMI and Medication Adherence from CAB
and CAR Scores.
β

SE β

B

t

p

Body Mass Index
(Constant)
Sex
Group
CAB
CAR
CAB  CAR

21.449
6.448
2.263
0.126
0.428
0.254

3.651
1.923
1.794
0.542
0.761
0.613

–
.162
.496
.031
.077
.056

5.992
1.177
3.594
0.233
0.562
0.400

.000
.246
.001
.817
.577
.691

Medication Adherence
(Constant)
Sex
Group
CAB
CAR
CAB  CAR

2.421
-0.099
1.009
-0.273
0.256
0.177

1.132
0.596
0.556
0.168
0.236
0.190

–
-.024
.265
-.229
.158
.139

1.966
-0.165
1.813
-1.628
1.083
0.931

.054
.869
.077
.111
.285
.357

Note: CAB = cardiac autonomic balance; CAR = cardiac autonomic regulation
With regard to BMI, the omnibus test of the full model was significant, F(5,44)=2.825,
p=.027, R2=.24, adjusted R2=.16. Within this model, only group membership (β=2.263) was a
significant predictor of BMI. With regard to medication adherence, the omnibus test of the full
model in the prediction failed to reach significance, F(5,44)=1.562, p=.191. These findings
should be interpreted with caution, however, because in both instances the null model remained
significant with the inclusion of the hypothesized indicator variables. As such, we cannot
conclude that these variables enhance prediction of BMI or medication adherence.
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CHAPTER FOUR: DISCUSSION
The purpose of this investigation was to further clarify the relationship between
metabolic abnormalities and autonomic dysregulation as measured by variations in CAC. In
support of this purpose, we used ambulatory ICG to measure physiological changes during
engagement in psychosocial stressors among 50 patients with and without metabolic syndrome.
We then compared these groups on a variety of cardiovascular measures to identify the extent to
which patterns of sympathovagal reactivity may be implicated in MetS, and whether such a
relationship may also impact health behavior and treatment adherence. To our knowledge, this is
the first study to examine whether individuals with and without MetS differ in regard to CAC in
the context of experimentally induced stress. We developed four aims to address our core
research questions. Each of these aims will be discussed in turn.
Our first aim was to verify the association between CAC and health status. In particular,
we set out to replicate previous findings that suggest CAB and CAR are related to certain chronic
conditions that develop as a result of MetS (i.e., type 2 diabetes and cardiovascular disease). We
hypothesized that CAC indices would predict diagnosis of these conditions in our sample; this
hypothesis gained partial support. As expected, CAR was a significant predictor of
cardiovascular disease, lending support to the original work by Berntson et al. (2008). This
finding indicated that within the full sample, individuals who evidenced a lower degree of coactivation between sympathetic and parasympathetic systems were more likely to be diagnosed
with cardiovascular disease. This association is conceptually and empirically well-supported, as
diminished sympathovagal co-activation may restrict the dispositional nature with which one
adapts to a stressor, and facilitating a cycle of maladaptive responding (Sloan et al, 1995).
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Despite this significant outcome, CAB was not a significant predictor of type 2 diabetes, a
finding that does not replicate the original work. There are likely several reasons for this null
finding, the most salient of which may be related to consistency of diabetes management across
the sample. While many measurements of HbA1C were missing from this sample, most of the
existing values were below 7.5, suggesting a relatively high degree of control of this chronic
condition and potentially decreased burden on the cardiovascular system.
In an effort to further examine the relationship between CAC and health status, we also
tested whether cardiovascular measures (including CAB and CAR) could predict self-reported
measures of psychosocial distress and quality of life while controlling for MetS diagnosis.
Contrary to our expectations, our models predicted only one of the quality of life domains
(environmental). We found higher LVET scores and lower CO scores were associated with
greater environmental quality of life. Higher LVET scores are often cited as a marker of
decreased sympathetic cardiac control; likewise, CO, which is largely related to myocardial
contractility3, may also serve as an indicator of sympathetic activation. These variables not only
predicted quality of life in this domain, but also did so in an expected direction, such that lower
sympathetic activation is associated with increased perceived environmental quality of life. Items
in this scale pertain to physical safety and security, accessibility and quality of health care, and
quality of physical environment, among others. It may be that individuals who respond with
decreased sympathetic cardiac control are more likely to engage in practices that support this

3

There are a host of additional variables that influence and/or change CO including pre-load,
after-load and heart rate (Vincent, 2008). However, because contractility is often indicative of
sympathetic cardiac control in non-exertive situations, it frequently denotes degree of
sympathetic activation.
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domain of quality of life. Our models did not predict anxiety or depression scores, however,
running contrary to our hypothesis. Failure to detect differences in these models may be due to a
relatively low degree of reported symptoms (i.e., restricted range) within these measures.
Our second hypothesis within this aim was to examine baseline differences in CAC and
related indices of sympathovagal activation between the MetS and HC groups. We hypothesized
that the MetS and HC groups would differ both on individual measures of sympathetic (PEP) and
parasympathetic (RSA) cardiac control, but also on the computed measures of CAB and CAR.
Contrary to expectations, baseline CAB and CAR scores did not differ between groups, even
when controlling for medication use and number of medical problems. Though unanticipated,
this finding nonetheless provides important information with regard to reactivity of the
experimental groups during experimentally induced stress. That is, this finding argues against the
notion that cardiovascular status individuals with MetS are fundamentally different at rest.
Instead, we submit that it is in the process of appraising and responding to external demands that
meaningful alterations emerge. These alterations, in turn, may provide the foundation for
negative health outcomes.
Our second and third experimental aims were directed at understanding this possibility
and were focused on examining CAC among patients with MetS during the two distinct
experimental tasks. These tasks comprised standardized mental arithmetic as well as a structured,
but flexible health and wellness interview. Prior to proceeding with these tests, we first verified
the effectiveness of our experimental relationship by examining changes in key psychological
variables across the full sample during the experimental task. We identified decreases in PEP
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during a number of the task segments, providing initial indication that our experimental task
elicited the expected response across the entire sample.
We hypothesized that individuals with MetS would evidence lower CAB and CAR scores
during the standardized Mental Arithmetic stressor. By virtue of the standardization, this stressor
was intended to provide a point-of-comparison for subsequent experimental tasks. Our findings
revealed that configuration of CAB and CAR responses to the arithmetic tasks were consistent
with expectation, but these differences failed to reach statistical significance. It is unlikely that
this null finding is an artifact of practice effects. Counterbalancing of experimental tasks was
crucial in order to verify group differences were due not to passage of time, but to the specific
experimental manipulation. The utility of using this stressor as a point-of-comparison is therefore
crucial in the context of examining hypothesized between-group differences during the other
stressors tasks.
Indeed, we observed such differences during distinct segments of the health and wellness
interview. These differences occurred both in PEP and RSA as well as the computed CAC
variables. Specifically, PEP among HC participants became longer during the medication and
diet segments, as compared to those with MetS. This difference was in the expected direction,
suggesting that HC participants responded with decreased sympathetic activity in response to
these segments.
Moreover, we found significant group-by-segment interaction in both CAB and CAR
scores that highlight how patterns of responses between experimental groups differed in the
context of distinct interview segments. CAB scores in the HC group generally increased across
the interview segments, peaking during the stress segment. The opposite pattern was observed in
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the MetS group, which evidenced generally decreasing CAB scores, with the lowest value
observed during the stress segment. That is, MetS participants demonstrated poorer
sympathovagal balance when discussing their daily stress as compared to HC patients. This
finding points to maladaptive psychological responses to an externally presented stressor (i.e.,
the interview questions), and it is potentially meaningful given its relevance to stress cues. It is
possible that patterns of appraisal observed here may become chronic and can therefore place an
individual at greater risk for negative health outcomes either by limiting the extent to which the
individuals maintains allostasis, or by increasing allostatic load. It may also be the case that the
topic presented during this experimental task provides a context in which the patient with MetS
may avoid stress cues.
Patterns of CAR scores during the interview segments were slightly different relative to
the corresponding pattern of CAB scores. Among HC participants, CAR scores were the lowest
in response to questions about medication adherence and trended upward thereafter, peaking
during the stress segment. Again, the opposite pattern was seen in MetS patients with highest
CAR scores observed during the medication segment. CAR scores then decreased gradually to
their lowest point, observed during the stress segment. This pattern indicates coactive
sympathovagal responses among MetS patients discussing medication adherence, in comparison
to HC participants, who responded with a lesser degree of sympathovagal co-activation to the
same questions. This finding, though unexpected, may support the notion that as medical
complexity increases, so too does the likelihood of a holding multiple medications prescription.
The MetS group, who evidenced more medical problems, may have a greater demand for regular
medication adherence, thereby demonstrating a greater degree of coactive autonomic control in
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response to this perceived demand. Conversely, HC participants who likely had fewer
medication concerns may not have appraised this segment in the same way, leading to a less
dramatic autonomic response.
We also set out to assess whether dominant motivational states (i.e., “challenge” vs.
“threat”) could be associated with MetS by examining variations in cardiac and vascular
reactivity to our experimental manipulation. Unfortunately, due to technological limitations of
the monitoring equipment, we were unable to verify that TPR readings corresponded to the
distinct start- and end-points of our stressor tasks, and therefore, we could not test whether
changes in TPR corresponded to experimental manipulation. Instead, we examined whether PEP
and TPR across the full experimental task (approximately 30 minutes) as an analogue. Initial
findings suggested that PEP, TPR, and an interaction term representing their combined effect
was predictive of MetS; however, we were unable to determine that specific indicators were
statistically associated with our outcome, so these models could not be interpreted. We then
attempted to compare MetS groups on PEP and TPR at each point of measurement to further
determine if distinct CV patterns underlying motivational state varied between HC and MetS
groups. Our primary hypothesis was not supported, however, as we were unable to detect
differences in PEP or TPR at sequential points of measurement. This null finding is most likely
due to the temporal staggering in both task engagement and baseline recovery across the sample.
Our final aim was to examine the influence of cardiac autonomic control on health
behaviors and treatment adherence among individuals with MetS. We hypothesized that lower
CAC would predict poorer health behaviors, higher BMI and poorer medication adherence.
Indeed, the hypothesis gained partial support. Across the whole sample, decreased CAR scores
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and male gender were associated with an increased likelihood of smoking, while controlling for
experimental group. This pattern may be representative of attempts to behaviorally regulate
sympathovagal activity. None of the other models suggested that CAB or CAR were predictive
of poor treatment adherence. Because these models failed to adequately predict the identified
outcomes, the indicator variables we measured cannot be used to explain patterns of disease
progression in MetS. It is possible that with a larger sample, these hypotheses could be addressed
with greater cogency and more vigorous conclusions may be drawn.
Limitations
A primary limitation of the present investigation pertains to experimental power and
external validity given current sample size. Most notably, statistical control of potentially
confounding variables becomes problematic in small samples, as inclusion of covariates expends
degrees of freedom. This concern was particularly relevant as we attempted to account for the
impact of CV medications on our outcome variables. For more robust hypothesis testing and
replication of the present findings, collection of data in a larger sample is warranted. Second, we
observed a number of missing data, primarily within the patients’ laboratory findings maintained
in their medical record. These particular data could not be imputed because they were not
missing at random; rather, they were collected (or not collected) based on best practice
guidelines of clinical care, which are directly related to disease status and progression. Indeed, if
these data were to be imputed, it would likely lead to biased estimates. Nonetheless, inclusion of
these observations would have allowed for a number of analyses that were not feasible in the
present data set (e.g., examination of MetS as a continuous variable thereby permitting
estimation of illness severity). A third limitation, as noted above, involved technological issues
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in BP measurement. Obtaining a non-continuous measure was the most logistically appropriate
option for this investigation but it presented a significant barrier when comparing cardiovascular
reactivity across experimental groups. Without a continuous measure of BP, and in view of the
necessarily variable boundaries of the experimental tasks, we could not compare participants’
TPR responses during task engagement. This circumstance limited out ability to test differences
along the domain of TPR reactivity, and by extension, to draw conclusions about how such
differences may potentiate the relationships described here. Finally, due to time restrictions we
were unable to collect objective measures of diet. Given the role of diet in MetS, these
measurements would have offered the opportunity to conduct additional analyses pertaining to
disease etiology and maintenance, which were not feasible in this study. This limitation is also
related to the problem of using the health behaviors measures here as an analogue of treatment
adherence.
Future Directions
The most important extension of this work would be to develop longitudinal, prospective
studies to examine the extent to which CAC and its constituent indicators may be implicated in
the etiology of MetS. Within this type of study design, longer periods of monitoring (e.g., over a
period of hours) across many days, weeks, or months may be helpful to clarify the timeline along
which etiological mechanisms operate. A particular strength of this kind of study could be
examination of other stressors types (e.g., medical visits vs. family interactions) to better
understand the circumstances within which stress is pathogenic. Additionally, our findings are
consistent with the notion that direct engagement in stress cues is associated with potentially
maladaptive responses among individuals with metabolic abnormalities. One implication of such
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findings is that certain patterns of reactivity contributes to disease maintenance, given the
established influence of stress in MetS; it is therefore possible that prototypical ‘profiles’ can be
observed among subgroups of individuals with MetS. Cluster or latent class analysis could help
uncover these subgroups of individuals. Similarly, understanding protective factors in this
population would offer an important perspective on minimizing the damaging effects of
dysregulated CAC. Coping may prove to be one such factor that could safeguard against
progression of MetS. Given the emphasis on behavioral interventions in managing stress,
examination of coping skills would serve as a crucial component of programmatic research in the
physiology of illness. Finally, repercussions of autonomic reactivity may be evident in other
systems, such as immune and endocrine reactivity (e.g., HPA-axis). Given the emerging
emphasis on inflammation as a cross-cutting feature of a number of diseases, including MetS
(Lee & Pratley, 2005), it would be valuable also to evaluate the extent to which autonomic
tendencies identified here contribute to patterns of immune functioning and/or inflammation.
Conclusions
As reviewed above, previous findings have supported the notion that psychological
appraisal in response to external demands are associated with physiological changes that may
have deleterious effects over time. Such evidence has been used to advance current etiological
models of MetS (Aubert & Raemaekers, 1999; Bellavere et al., 1992; Krzesinski, Gielerak, &
Kowal, 2013; Malliani, 2005; McGrady, 2010). The findings of the present study also contribute
to this existing body of evidence, supporting psychological contributions to physical illness and
may offer additional information about the conditions under which psychological reactivity is
involved in disease progression.
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Though limitations exist, this study has implications both for assessment and treatment
monitoring, especially given the potential relationship between CAC and health and wellness
ques presented here. On-going hemodynamic evaluation of individuals with MetS would allow
application of basic physiological concepts to relevant real-world settings in order to predict
patient outcomes and response to treatment. Notably, the ambulatory nature of these monitoring
procedures is consistent with ongoing efforts to enhance mobile health (mHealth) and can even
inform remote delivery of clinical interventions such as biofeedback. Crucially, our results can
be applied to preventative efforts to help individuals at risk for metabolic syndrome identify and
thereby alter responses to stress.
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APPENDIX A: DESCRIPTIVE STATISTICS FOR STUDY VARIABLES BY
EXPERIMENTAL GROUP
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Appendix A: Descriptive Statistics for Study Variables by Experimental Group
Healthy Control (N=25)

Baseline PEP
Baseline RSA
Baseline CAB
Baseline CAR
HWI, Medication
PEP
RSA
CAB
CAR
HWI, Diet
PEP
RSA
CAB
CAR
HWI, Exercise
PEP
RSA
CAB
CAR
HWI, Stress
PEP
RSA
CAB
CAR
HWI, Coping
PEP
RSA
CAB
CAR
MA, Serial 7s
PEP
RSA
CAB
CAR
MA, Multiplication
PEP
RSA
CAB
CAR

Metabolic Syndrome (N=25)

M (SD)

Range

M (SD)

Range

89.36 (22.04)
4.75 (1.20)
-0.24 (1.59)
0.05 (1.16)
–
88.40 (25.77)
4.95 (1.20)
-0.12 (1.44)
-0.01 (1.28)
–
87.68 (24.14)
5.04 (1.27)
-0.01 (1.56)
0.02 (1.10)
–
86.88 (26.36)
5.15 (1.30)
0.05 (1.49)
0.26 (1.19)
–
86.72 (24.21)
5.34 (1.22)
0.20 (1.48)
0.38 (1.16)
–
86.56 (24.92)
4.85 (1.46)
-0.10 (1.61)
0.10 (1.28)
–
84.48 (24.58)
4.72 (1.36)
0.02 (1.54)
0.25 (1.13)
–
84.88 (22.91)
5.01 (1.22)
0.05 (1.40)
0.29 (1.06)

50.00–126.00
2.66–7.23
-3.13–2.61
-1.99–2.92
–
54.00–134.00
2.72–7.59
-3.02–2.65
-2.94–2.25
–
56.00–128.00
2.60–7.74
-2.75–2.46
-1.78–2.08
–
50.00–132.00
1.46–7.44
-2.54–2.78
-2.56–1.83
–
54.00–132.00
2.79–8.08
-2.30–3.07
-2.14–2.42
–
52.00–130.00
1.21–7.73
-2.81–2.54
-2.87–2.08
–
54.00–132.00
1.59–7.31
-2.29–2.60
-2.15–2.43
–
54.00–124.00
2.96–6.86
-2.13–2.80
-1.90–2.29

96.16 (25.80)
4.97 (1.11)
0.24 (1.63)
-0.05 (1.24)
–
91.12 (25.93)
5.12 (1.43)
0.12 (1.55)
0.01 (1.42)
–
88.56 (28.06)
5.02 (1.36)
0.01 (1.40)
-0.02 (1.59)
–
92.56 (29.12)
4.73 (1.41)
-0.05 (1.58)
-0.26 (1.37)
–
91.44 (28.60)
4.60 (1.23)
-0.20 (1.47)
-0.39 (1.45)
–
92.00 (28.36)
4.84 (1.17)
0.10 (1.39)
-0.10 (1.39)
–
90.56 (28.63)
4.34 (1.40)
-0.02 (1.63)
-0.25 (1.31)
–
91.12 (28.64)
4.52 (1.56)
-0.05 (1.55)
-0.29 (1.59)

68.00–142.00
2.87–7.58
-1.91–3.85
-3.78– 1.73
–
64.00–148.00
2.46–7.74
-2.34–3.79
-3.92–2.50
–
46.00–146.00
2.61–7.10
-2.12–2.43
-3.94–2.36
–
62.00–146.00
2.50–7.84
-2.43–2.32
-3.06–2.63
–
64.00–142.00
2.59–6.85
-2.57–2.68614
-3.79–1.53452
–
64.00–144.00
2.99–7.00
-1.99–2.35
-3.25–1.95
–
64.00–148.00
1.86–6.89
-2.77–2.75
-3.23–2.30
–
62.00–144.00
1.98–7.88
-2.90–2.78
-3.97–2.75
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Appendix Table A (continued)
Healthy Control (N=25)

TPR (dyn·s·cm−5)
300 sec
600 sec
900 sec
1200 sec
1500 sec
1800 sec
PEP (milliseconds)
300 sec
600 sec
900 sec
1200 sec
1500 sec
1800 sec
Self-Report Measures
HADS-A
HADS-D
QOL – Physical
QOL – Psychological
QOL – Social
QOL – Environmental
MMAS

Metabolic Syndrome (N=25)

M (SD)

Range

M (SD)

Range

–
6.05 (2.39)
5.44 (1.87)
5.79 (2.71)
5.56 (2.09)
6.17 (2.93)
5.88 (2.18)
–
86.56 (23.86)
90.42 (24.22)
82.00 (24.69)
84.64 (22.78)
85.76 (24.30)
87.75 (23.34)
–
6.76 (3.42)
3.76 (2.44)
15.09 (3.36)
14.96 (2.49)
14.45 (3.52)
16.21 (2.78)
2.36 (1.73)

–
2.84–10.07
2.75–9.65
2.75–14.42
2.13–10.40
2.26–12.94
2.88–9.67
–
48.00–132.00
52.00–126.00
48.00–128.00
42.00–134.00
50.00–132.00
44.00–122.00
–
1.00–13.00
0.00–8.00
7.43–20.00
11.33–19.33
8.00–20.00
9.00–20.00
1.00–7.00

–
6.05 (3.23)
6.75 (3.99)
6.36 (3.35)
5.63 (2.37)
5.98 (3.09)
6.63 (3.41)
–
90.16 (27.11)
94.40 (29.42)
98.40 (27.09)
98.40 (28.48)
98.88 (27.56)
95.23 (26.11)
–
7.12 (3.74)
5.12 (3.34)
13.58 (2.95)
13.70 (3.07)
12.32 (3.32)
15.88 (2.63)
3.16 (2.06)

–
2.51–17.06
3.11–16.81
2.29–15.64
2.38–11.22
2.51–14.34
2.97–15.03
–
58.00–146.00
58.00–148.00
58.00–150.00
60.00–152.00
58.00–144.00
58.00–150.00
2.00–14.00
1.00–13.00
8.57–18.29
7.33–17.33
6.67–20.00
10.50–20.00
2.00–8.00

Note: CAB = PEP = pre-ejection period; RSA = respiratory sinus arrhythmia; Cardiac
Autonomic Balance; CAR = Cardiac Autonomic Control; HWI – Health and Wellness Interview;
MA = Mental Arithmetic; TPR = total peripheral resistance; PEP = pre-ejection period; HADSA= Hospital Anxiety and Depression – Anxiety Scale Score; HADS-D= Hospital Anxiety and
Depression – Depression Scale Score; QOL – Physical = WHO Quality of Life–Brief–Physical
Domain; QOL – Psychological = WHO Quality of Life–Brief–Psychological Domain; QOL –
Social = WHO Quality of Life–Brief –Social Domain; QOL – Environmental = WHO Quality of
Life–Brief–Environmental Domain; MMAS = Morisky Medication Adherence Scale Total
Score.
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Mental Arithmetic
Directions:
I am interested in how you perform a couple of metal math calculations. In a moment, I will ask you to
perform some subtraction problems. When I say to, I want you to subtract 7 from 100 and continue
subtracting 7 from each subsequent answer. Please continue until I tell you to stop. Do you have any
questions?”
“Ready? Begin” Begin timing for 1 minute.
Start Time: _____: _____: _____
End Time: ______: _____: _____
Correct answers (left to right):

NOTE: For each incorrect answer, instruct the participant: “Incorrect. Please begin again.”
100

93

86

79

72

65

58

51

44

37

30

23

16

9

2

-5

-12

-19

-26

-33

-40

-47

-54

-61

-68

-75

-82

-89

-96

-103

“Thank you. Next, I would like you to multiply 4 by 3 and continue multiplying each answer by 3 until I
tell you to stop. Do you have any questions?”
“Ready? Begin” Begin timing for 1 minute.
Start Time: _____: _____: _____
End Time: ______: _____: _____

NOTE: For each incorrect answer, instruct the participant: “Incorrect. Please begin again.”
12

36

108

324

972

2,916

8,748

26,244

78,732

236,196

708,588

2,125,764
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Health and Wellness Interview
Directions:
“I am interested in understanding any difficulties you have had with your health and wellness. In particular, I would
like to know about your experience taking medication, following a healthy diet, being physically active, stress
patterns and coping.”

Start Time: ______: _____: _____ End Time: ______: _____: _____

I. Medical Adherence

“Are you taking your prescription medication regularly?”

☐Yes

☐No

“What barriers do you perceive to taking your medication?”
☐Inconvenient

☐Cost

☐Side Effects

☐Not Important

☐Not Motivated

☐Forget

Other/Notes:

Start Time: ______: _____: _____ End Time: ______: _____: _____

II. Nutrition
“Are you following a healthy diet?”

☐Yes

☐No

“What barriers do you perceive to following a healthy diet?”
☐Inconvenient

☐Cost

☐Time/Energy

☐Not Important

☐Not Motivated

☐Forget

Other/Notes:

Start Time: ______: _____: _____ End Time: ______: _____: _____

III. Exercise
“Are you getting regular exercise?”

☐Yes

☐No

“What barriers do you perceive to getting regular exercise?”
☐Inconvenient

☐Pain

☐Time/Energy

☐Not Important

☐Not Motivated

☐Forget

Other/Notes:

Start Time: ______: _____: _____ End Time: ______: _____: _____

IV. Stress

“Are you feeling stress from everyday hassles?”

☐Yes

☐No

☐Housing

☐School

“What areas in particular do you find most stressful”
☐Finances

☐Employment

☐Home Life

☐Health

☐Relationships

Other/Notes:
“On a scale of 0 to 10, with 10 being the most stress, how much stress do you feel on a daily basis?
0

1

2

3

4

5

6

7

8

9

10

Start Time: ______: _____: _____ End Time: ______: _____: _____

V. Coping

“Are you managing your stress very well?”

☐Yes

☐No

“What barriers do you perceive to managing your stress?”
☐Knowledge

☐Ability

☐Relationships

☐Responsibilities

Other/Notes:
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☐Not Motivated

☐Unimportant
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